

# PSOGI VENICE 2023




The 13<sup>th</sup> PSOGI International Congress  
on Peritoneal Surface Malignancies

October 4<sup>th</sup> - 6<sup>th</sup>, 2023

Palazzo del Cinema - Venice Lido

[www.psogicongress2023.com](http://www.psogicongress2023.com)



# The 13<sup>th</sup> PSOGI International Congress on Peritoneal Surface Malignancies

is realized with the patronage of:



SOCIETÀ ITALIANA  
DI CHIRURGIA  
ONCOLOGICA  
ESSO AFFILIATED

## Congress Chairs

### Marcello Deraco

Director Peritoneal Surface Malignancies Unit  
 “Fondazione IRCCS Istituto Nazionale dei Tumori” - Milan (Italy)

### Paolo Sammartino

Director CRS-HIPEC Unit “Dipartimento Valdoni”  
 Sapienza University - Rome (Italy)

## Congress President

### Paul H. Sugarbaker

Secretary General of PSOGI & Director of Center  
 for Gastrointestinal Malignancies,  
 MedStar Washington Hospital Center - Washington (USA)

## Scientific Committee

### PSOGI Board

**Mohammad Alyami** - Najran (Saudi Arabia)

**Aditi Bhatt** - Ahmedabad (India)

**Ignace de Hingh** - Eindhoven (The Netherlands)

**Olivier Glehen** - Lyon (France)

**Diane Goéré** - Paris (France)

**Santiago González-Moreno** - Madrid (Spain)

**Yan Li** - Beijing (China)

**Brendan John Moran** - Basingstoke (United Kingdom)

**David Morris** - Sydney (Australia)

**Aviram Nissan** - Tel Aviv (Israel)

**Pompiliu Piso** - Regensburg (Germany)

**Claudio Quadros** - Salvador (Brasil)

**Beate Rau** - Berlin (Germany)

**S.P. Somashekhar** - Bangalore (India)

**Vic Verwaal** - Lund (Sweden)

**Yutaka Yonemura** - Kanazawa City (Japan)

## Organizing Committee

### Onco Team SICO PSM

**Marco Vaira** - Coordinator - Candiolo (Italy)

**Luca Ansaloni** - Pavia (Italy)

**Giovanni De Manzoni** - Verona (Italy)

**Andrea Di Giorgio** - Rome (Italy)

**Massimo Framarini** - Forlì (Italy)

**Roberta Gelmini** - Modena (Italy)

**Piero Vincenzo Lippolis** - Pisa (Italy)

**Antonio Macri** - Messina (Italy)

**Enrico Maria Pasqual** - Udine (Italy)

**Franco Roviello** - Siena (Italy)

**Cinzia Sarraroli** - Naples (Italy)

**Antonio Sommariva** - Padua (Italy)

**Mario Valle** - Rome (Italy)

## Scientific Secretary

**Dario Baratti** - Milan (Italy)

**Daniele Biacchi** - Rome (Italy)

**Maurizio Cardi** - Rome (Italy)

**Tommaso Cavalleri** - Milan (Italy)

**Marcello Guaglio** - Milan (Italy)

**Shigeki Kusamura** - Milan (Italy)

**Rea Lo Dico** - Rome (Italy)

Paul H. Sugarbaker, *Washington (USA)*  
Mohammed Alyami, *Najran (Arabia Saudita)*  
Luca Ansaloni, *Pavia (Italy)*  
Alvaro Arjona Sanchez, *Cordoba (Spain)*  
Omer Aziz, *Manchester (UK)*  
Brian Badgwell, *Houston (USA)*  
Noual Bakrin, *Lyon (France)*  
Dario Baratti, *Milano (Italy)*  
Jorge Barriuso, *Manchester (UK)*  
Aditi Bhatt, *Ahmedabad (India)*  
Daniele Biacchi, *Roma (Italy)*  
Lana Bijelic, *Barcelona (Spain)*  
Andreas Brandl, *Haidelberg (Germany)*  
Donald Brennan, *Dublin (Ireland)*  
Pedro Bretcha, *Torreveija (Spain)*  
Maurizio Cardi, *Roma (Italy)*  
Pedro Cascales, *Murcia (Spain)*  
Patrick Caswell, *Manchester (UK)*  
Tommaso Cavalleri, *Milano (Italy)*  
Wim Ceelen, *Ghent (Belgium)*  
Bipasha Chakrabarty, *Manchester (UK)*  
Claramae Chia Shulyn, *Singapore (Republic of Singapore)*  
Vito Chiantera, *Palermo (Italy)*  
Michela Cinquini, *Milano (Italy)*  
Jean Marc Classe, *Nantes (France)*  
Delia Cortes Guiral, *Madrid (Spain)*  
Franco De Cian, *Genova (Italy)*  
Ignace De Hingh, *Eindhoven (The Netherlands)*  
Giovanni De Manzoni, *Verona (Italy)*  
Ruggero De Maria, *Roma (Italy)*  
Paolo Delrio, *Napoli (Italy)*  
Marcello Deraco, *Milano (Italy)*  
Andrea Di Giorgio, *Roma (Italy)*  
Clarisse Dromain, *Lausanne (Switzerland)*  
Jesus Esquivel, *Lewes (UK)*  
Clarisse Eveno, *Lille (France)*  
Anna Fagotti, *Roma (Italy)*  
Mohammed Faheez, *Basingstoke (UK)*  
Massimo Framarini, *Forli (Italy)*  
Manuela Gariboldi, *Milano (Italy)*  
Roberta Gelmini, *Modena (Italy)*  
Olivier Glehen, *Lyon (France)*  
Diane Göcércé, *Paris (France)*  
Santiago Gonzalez Moreno, *Madrid (Spain)*  
Marcello Guaglio, *Milano (Italy)*  
Martin Hübner, *Lausanne (Switzerland)*  
Franco Iafrate, *Roma (Italy)*

Vahan Kepenekian, *Lyon (France)*  
Hedy Kindler, *Chicago (USA)*  
Shigecki Kusamura, *Milano (Italy)*  
Andrea Laghi, *Roma (Italy)*  
Edward Levine, *Winston-Salem (USA)*  
Yan Li, *Beijing (China)*  
Vincenzo Lippolis, *Pisa (Italy)*  
Rea Lo Dico, *Roma (Italy)*  
Antonio Macri, *Messina (Italy)*  
Andrea Mingoli, *Roma (Italy)*  
Brendan Moran, *Basingstoke (UK)*  
David Morris, *Sydney (Australia)*  
Aviram Nissan, *Tel Aviv (Israel)*  
Sarah O'Dwyer, *Manchester (UK)*  
Enrico Maria Pasqual, *Udine (Italy)*  
Pompiliu Piso, *Regensburg (Germany)*  
Marc Pocard, *Paris (France)*  
Kees Punt, *Utrecht (The Netherlands)*  
Claudio Quadros, *Salvador (Brazil)*  
Francois Quenet, *Barcelona (Spain)*  
Beate Rau, *Berlin (Germany)*  
Artur Reis, *Sao Paulo (Brazil)*  
Marc Reymond, *Tübingen (Germany)*  
Daniele Marrelli, *Siena (Italy)*  
Paolo Sammartino, *Roma (Italy)*  
Armando Sardi, *Baltimore (USA)*  
Rafael Seitenfus, *Porto Alegre (Brazil)*  
Olivia Sgarbura, *Montpellier (France)*  
Cristina Smolenschi, *Paris (France)*  
SP Somashekhar, *Bangalore (India)*  
Antonio Sommariva, *Padova (Italy)*  
John Spiliotis, *Athens (Greece)*  
Cem Terzi, *Izmir (Turkey)*  
Kiran K Turaga, *Chicago (USA)*  
Marco Vaira, *Candiolo (Italy)*  
Mario Valle, *Roma (Italy)*  
Kurt Van der Speeten, *Ghent (Belgium)*  
Willemien Van Driel, *Amsterdam (The Netherlands)*  
Vic Verwaal, *Lund (Sweden)*  
Laurent Villeneuve, *Lyon (France)*  
Bruno Vincenzi, *Roma (Italy)*  
Kostantinos Votanopoulos, *Winston-Salem (USA)*  
Yutaka Yonemura, *Kanzawa City (Japan)*

## The 13<sup>th</sup> PSOGI International Congress on Peritoneal Surface Malignancies


# PROGRAM AT A GLANCE

OCTOBER 4 <sup>th</sup>	PLENARY ROOM	PASINETTI ROOM
07.30 - 08.45	REGISTRATION	
08.45 - 09.00	<b>CONGRESS OPENING</b> <i>Marcello Deraco (Milan), Paolo Sammartino (Rome), Paul H. Sugarbaker (Washington)</i>	
09.00 - 10.30	<b>SESSION I   CONSENSUS</b> PSOGI HIPEC RECOMMENDATIONS	
10.30 - 11.00	Coffee Break	
11.00 - 13.00	<b>SESSION II   ORAL ABSTRACT</b> COLORECTAL CANCER	<b>SESSION I-P   ORAL ABSTRACT</b> DIAGNOSIS AND STAGING ON PERITONEAL SURFACE MALIGNANCIES
13.00 - 14.00	Lunch - Poster Viewing and Discussion	
14.00 - 14.30	<b>THE PSOGI INTERVIEW</b> Peritoneal Surface Malignancies We have come a long way; we have a long way to go <i>Paul H. Sugarbaker (Washington)</i>	
14.30 - 16.00	<b>SESSION III   ORAL ABSTRACT</b> APPENDICEAL NEOPLASMS AND PSEUDOMYXOMA PERITONEI	<b>SESSION II-P   ORAL ABSTRACT</b> PIPAC
16.00 - 16.30	Break	
16.30 - 17.30	<b>SESSION IV   ORAL ABSTRACT</b> CLINICAL TRIALS AND REGISTRIES	
17.30 - 18.35		

OCTOBER 5 <sup>th</sup>	PLENARY ROOM	PASINETTI ROOM
07.30 - 08.30		
08.30 - 10.30	<b>SESSION V   CONSENSUS</b> PSOGI/MULTISOCIETIES RECOMMENDATIONS FOR MANAGEMENT OF PSM	
10.30 - 11.00	<i>Coffee Break</i>	
11.00 - 12.00	<b>SESSION VI   ORAL ABSTRACT</b> EPITHELIAL OVARIAN CANCER AND SEROUS PRIMARY PERITONEAL CARCINOMA	<b>SESSION III-P   ORAL ABSTRACT</b> NURSES MANAGEMENT OF PERITONEAL SURFACE MALIGNANCIES
12.00 - 13.00		<b>SESSION IV-P   ORAL ABSTRACT</b> TECHNIQUE ADVANCEMENT ON CRS-HIPEC
13.00 - 14.00	<i>Lunch - Poster Viewing and Discussion</i>	
14.00 - 14.30	<b>CHARITIES AND PATIENTS' EXPERIENCES</b>	
14.30 - 16.00	<b>SESSION VII   ORAL ABSTRACT</b> PERITONEAL MESOTHELIOMA	<b>SESSION V-P   ORAL ABSTRACT</b> PERIOPERATIVE CARE
16.00 - 16.30	<i>Break</i>	
16.30 - 18.00	<b>SESSION VIII   ORAL ABSTRACT</b> BASIC & TRASLATIONAL RESEARCH	
OCTOBER 6 <sup>th</sup>	PLENARY ROOM	PASINETTI ROOM
07.30 - 08.30		
09.00 - 10.30	<b>SESSION IX   ORAL ABSTRACT</b> GASTRIC CANCER	<b>SESSION VI-P   ORAL ABSTRACT</b> LAPAROSCOPIC CRS HIPEC
10.30 - 11.00	<i>Break</i>	
11.00 - 11.20	<b>PLENARY LECTURE</b> EMERGENT TECHNOLOGIES IN HEALTH CARE	
11.20 - 12.25	<b>SESSION X</b> TRAINING & TACHING ON PSM	
12.25 - 13.00	<b>ROUND TABLE</b> REPRESENTATIVE SPECIALIZATION SCHOOLS	
13.00 - 13.30	<b>PRESENTATION OF THE NEXT PSOGI CONGRESS</b> AWARDS AND CLOSING CEREMONY	

# Scientific Program

The 13<sup>th</sup> PSOGI International Congress  
on Peritoneal Surface Malignancies





## PLENARY ROOM

07.30 - 08.45 | **REGISTRATION**

08.45 - 09.00 | **CONGRESS OPENING**

*M. Deraco (Milan), P. Sammartino (Rome), P. H. Sugarbaker (Washington)*

09.00 - 10.30 | **SESSION I | CONSENSUS**

**PSOGI HIPEC RECOMMENDATIONS**

Chairpersons: *O. Glehen (Lyon), M. Deraco (Milan)*

09.00 | Introduction

*M. Deraco (Milan)*

09.05 | Methodology

*O. Glehen (Lyon)*

09.15 | Technical common questions on HIPEC

*K. Van der Speeten (Ghent)*

09.25 | Use of HIPEC in peritoneal mesothelioma

*V. Kepenekian (Lyon)*

09.35 | Use of HIPEC in pseudomyxoma peritonei

*S. Kusamura (Milan)*

09.45 | Use of HIPEC in peritoneal metastatic colorectal cancer

*M. Hübner (Lausanne)*

09.55 | Use of HIPEC in peritoneal metastatic ovarian cancer

*A. Bhatt (Ahmedabad)*

10.05 | Use of HIPEC in peritoneal metastatic gastric cancer

*C. Eveno (Lille)*

10.15 | Discussion

10.30 - 11.00 | **Coffee Break**

11.00 - 13.00 | **SESSION II | ORAL ABSTRACT**

**COLORECTAL CANCER**

Chairpersons: *V. Verwaal (Lund), F. Quenet (Barcelona)*

11.00 | **Keynote Lecture 1**

Prevention and Treatment of Peritoneal Metastases from Colorectal Cancer

*I. De Hingh (Eindhoven)*

11.15 | **Advancements on Medical Treatment in the Era of Immunotherapy**

*Cristina Smolenschi (Paris)*

11.30 | **Role of derived Organoids in the clinical management of colorectal peritoneal metastases**

*D. Baratti (Milan)*

- 11.45 | The effect of peri-operative chemotherapy response on survival for patients with colorectal cancer peritoneal metastases undergoing CRS + HIPEC  
*N. Tinsley (Manchester)*
- 11.55 | 18-month safety and efficacy after intraperitoneal treatment with 224Radium-labelled microparticles (Radspherin) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for colorectal peritoneal metastasis (PM)  
*S.G. Larsen (Oslo)*
- 12.05 | The poor prognosis of patients with peritoneal metastases of BRAF mutated colorectal cancer undergoing CRS-HIPEC is carried by the BRAF-TP53 co-mutated subgroup.  
*A.G.J. Aalbers (Amsterdam)*
- 12.15 | KRAS in colorectal peritoneal metastases treated with Cytoreductive Surgery and HIPEC: are all mutation subtypes equal?  
*M. Tonello (Padua)*
- 12.25 | Treating peritoneal relapse after previous cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastatic disease – a Swedish national peritoneal oncology group study  
*P. Harald Cashin (Uppsala)*
- 12.35 | Peritoneal Recurrence following CRS+HIPEC (MMC+OX) for CRC PM  
*D. Sabia (Barcelona)*
- 12.45 | Clinical Case Discussion  
*C. Terzi (Izmir)*

13.00 - 14.00 | Lunch - Poster Viewing and Discussion

14.00 - 14.30 | THE PSOGI INTERVIEW

Interviewers: *D. Morris (Sydney), B. Moran (Basingstone)*

THE PSOGI INTERVIEWED:

*P. H. Sugarbaker (Washington)*

“Peritoneal Surface Malignancies: We have come a long way; we have a long way to go”

14.30 - 16.00 | SESSION III - ORAL ABSTRACT

APPENDICEAL NEOPLASMS AND PSEUDOMYXOMA PERITONEI

Chairpersons: *M. Faheez (Basingstoke), S. O'Dwyer (Manchester)*

- 14.30 | Keynote Lecture II  
Pseudomyxoma Peritonei: a rare neoplasm with frequently unexpected natural history  
*B. Moran (Basingstoke)*
- 14.45 | Is there a role for the medical treatment of inoperable PMP?  
*Cristina Smolenschi (Paris)*
- 15.00 | Appendiceal Carcinoma: indications and limits of CRS HIPEC  
*V. Verwaal (Lund)*

- 15.10 | Prognosis Conferred by Molecular Features of Appendix-derived Pseudomyxoma Peritonei  
*R. Ma (Beijing)*
- 15.20 | Intratumoral Bromelain and Acetylcysteine for Recurrent and Unresectable Pseudomyxoma Peritonei. Final Results of a Phase I/II, unicentric clinical trial  
*A. Arjona Sanchez (Cordoba)*
- 15.30 | Accelerator Award on PMP  
*O. Aziz (Manchester)*
- 15.40 | Pseudovax - a therapeutic cancer vaccine targeting mutated GNAS in PMP  
*K. Flatmark (Oslo)*
- 15.50 | Clinical Case Discussion  
*C. Quadros (Salvador)*

16.00 - 16.30 | **Break**

16.30 - 18.35 | **SESSION IV - ORAL ABSTRACT  
CLINICAL TRIALS AND REGISTRIES**  
Chairpersons: *J. M. Classe (Bordeaux), L. Villeneuve (Lyon)*

- 16.30 | Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: The CHIPOR randomized phase III trial  
*O. Glehen (Lyon)*
- 16.45 | HIPEC T4  
*A. Arjona Sanchez (Cordoba)*
- 17.00 | Update on CAIRO6: past, present and future of a multicenter, phase II-III randomized superiority trial  
*T. Van den Heuvel (Eindhoven)*
- 17.15 | National Registry of the Spanish Group of Peritoneal Oncologic Surgery (REGECOP): Morbidity of 4159 scheduled procedures with HIPEC  
*F. Pereira (Madrid)*
- 17.30 | Colorectal cohort analysis from the Intraperitoneal Chemotherapy After Cytoreductive Surgery for Peritoneal Metastasis (ICARuS) clinical trial  
*N. Garret (New York)*
- 17.45 | Hyperthermic intraoperative peritoneal chemotherapy (HIPEC) for people with peritoneal metastases from colorectal, ovarian or gastric origin: A systematic review of randomised controlled trials  
*K. Selvan Gurusamy (London)*
- 18.00 | Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial  
*E. Madsen (Rotterdam)*

## PLENARY ROOM

- 18.15 | PSOGI Registries on Peritoneal Mesothelioma and Pseudomyxoma Peritonei  
*S. Kusamura (Milan)*
- 18.25 | Mucinous Appendiceal Neoplasms: Multi-Institutional Registry  
*M. Guaglio (Milan)*

08.30 - 10.30 | **SESSION V | CONSENSUS**  
**PSOGI/MULTISOCIETIES RECOMMENDATIONS FOR MANAGEMENT OF PSM**  
Chairpersons: *S. Kusamura (Milan), D. Brennan (Dublin)*

- 08.30 | Introduction  
*M. Deraco (Milan)*
- 08.40 | Methodology  
*M. Cinquini (Milan)*
- 08.55 | Peritoneal Mesothelioma  
*D. Morris (Sydney)*
- 09.05 | Pseudomyxoma Peritonei  
*E. Levine (Winston-Salem)*
- 09.15 | Discussion
- 09.25 | Gastric Cancer  
*B. Badgwell (Houston)*
- 09.40 | Colorectal Cancer  
*D. Góéré (Paris)*
- 09.55 | Discussion
- 10.10 | Ovarian cancer  
*D. Brennan (Dublin)*
- 10.25 | Discussion

10.30 - 11.00 | **Coffee Break**

11.00 - 13.00 | **SESSION VI | ORAL ABSTRACT**  
**EPITHELIAL OVARIAN CANCER AND SEROUS PRIMARY PERITONEAL CARCINOMA**  
Chairpersons: *S.P. Somashekhar (Bangalore), A. Fagotti (Rome)*

- 11.00 | **Keynote Lecture III**  
Has Ovarian Cancer first line management really changed in the era of HIPEC  
Randomized Clinical Trials?  
*W. Van Driel (Amsterdam)*

October 4<sup>th</sup>

October 5<sup>th</sup>

- 11.15 | Is there a role for HIPEC in the treatment of Recurrent Ovarian Cancer?  
*A. Fagotti (Rome)*
- 11.30 | **Keynote Lecture 9**  
Innovations & Surgical Considerations in Ovarian Cancer Management Enhancing Outcomes through Precise Surgical Techniques: Insights from Indian HIPEC ISPSM Registry  
*S.P. Somashekhar (Bangalore)*
- 11.45 | Off the Beaten Gynaecological Path: Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Ovarian Cancer in Austria  
*F. Laminger (Vienna)*
- 11.55 | Reduction of ileo/colostomy rate after introduction HIPEC for ovarian cancer as standard practice  
*A. Belt (Utrecht)*
- 12.05 | Radiomics-CT Sarcopenia Model to Predict Major Postoperative Complications in Ovarian Cancer Patients Undergoing CRS/HIPEC  
*F. Lopez Ramirez (Baltimore)*
- 12.15 | Cytoreductive Surgery with HIPEC as Primary Treatment for Advanced Epithelial Ovarian Carcinoma: Upfront or Interval - ISPSM Collaborative study  
*A.M. Fernandez (Bangalore)*
- 12.25 | Sites and presentation of recurrence in patients undergoing total parietal peritonectomy during interval cytoreductive surgery for advanced ovarian cancer- preliminary results from the TORPEDO study  
*A. Bhatt (Ahmedabad)*
- 12.35 | Safety and Efficacy of Total Neoadjuvant Therapy (TNT) combined with Cytoreduction and Carboplatin HIPEC in Advanced and Recurrent Ovarian Cancer based on Survival and Peritoneal Control  
*J. Foster (Omaha)*
- 12.45 | Surgical PCI vs Pathologic PCI – in Stage IIIC /IVA Carcinoma Ovary after Interval cytoreductive surgery and HIPEC  
*S. Sinukumar (Kozhikode)*
- 12.55 | Management of Serous Papillary Peritoneal Carcinoma  
*M. Guaglio (Milan)*
- 13.05 | Clinical Case Discussion  
*V. Chiantera (Palermo)*

---

13.00 - 14.00 | **Lunch - Poster Viewing and Discussion**

---

14.00 - 14.30 | CHARITIES AND PATIENTS' EXPERIENCES

14.30 - 16.00 | SESSION VII | ORAL ABSTRACT

PERITONEAL MESOTHELIOMA

Chairpersons: *K. K. Turaga (Chicago), P. H. Sugarbaker (Washington)*

14.30 | Keynote Lecture IV

Peritoneal Mesothelioma: The impact of 30 years of translational research on patient selection to CRS HIPEC

*M. Deraco (Milan)*

14.50 | Medical options for Peritoneal Mesothelioma

*H. Kindler (Chicago)*

15.10 | Optimizing adjuvant chemotherapy for malignant peritoneal mesothelioma based on patient derived tumor-like cell clusters drug testing

*Y. Li (Beijing)*

15.20 | Nationwide ten-year treatment evaluation in French centers for 924 patients with diffuse malignant peritoneal mesothelioma

*C. Eveno (Lille)*

15.30 | Safety and Clinical Efficacy of \_PD-1-mesoCAR-T (Mesothelin-specific CAR-T cells with Self-secreting PD-1 Nanobodies) in Patients with Malignant Peritoneal Mesothelioma

*Y. Sun (Beijing)*

15.40 | Intratumoral heterogeneity of peritoneal malignant mesothelioma

*M. L. Calabrò (Padua)*

15.50 | Clinical Case Discussion CRS and HIPEC for Multicystic Mesothelioma

*S. Almwollad (Najran)*

16.00 - 16.30 | Break

16.30 - 18.00 | SESSION VIII | ORAL ABSTRACT

BASIC & TRASLATIONAL RESEARCH

Chairpersons: *M. Pocard (Paris), P. Caswell (Manchester)*

16.30 | Keynote Lecture 5

Basic and Translational research on Peritoneal Surface Malignancies

*W. Ceelen (Ghent)*

16.45 | Organoids Technology application in PSM: bench to bedside

*K. Votanopoulos (Winston-Salem))*

17.00 | Intraperitoneal administration of carcinoembryonic antigen-directed CAR-T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal I cancer

*S. Qian (Madrid)*

- 17.10 | Metastatic peritoneal fibroblasts mobilize and respond to TGF-B1 from the extracellular matrix of colorectal cancer  
*C. Ramos (Vienna)*
- 17.20 | A Combinatorial Culture Strategy to Develop 3D Organoids from Pseudomyxoma Peritonei  
*L. Varinelli (Milan)*
- 17.30 | Pre-clinical models reveal new therapeutic opportunities for Pseudomyxoma Peritonei  
*J. Martinez Quitanilla (Barcelona)*
- 17.40 | Intraperitoneal administration of thermogel combined with an anticancer agent for the prevention of peritoneal carcinomatosis in a pig model.  
*M. Pocard (Paris)*
- 17.50 | A novel nanoparticle-based platform for intraperitoneal treatment of peritoneal metastases from ovarian and colorectal cancer  
*K.G. Fleten (Oslo)*

09.00 - 10.30 | SESSION IX | ORAL ABSTRACT

GASTRIC CANCER

Chairpersons: *D. Marrelli (Siena), P. Sammartino (Rome)*

- 09.00 | Keynote Lecture VI  
The role of Intra Peritoneal Chemotherapy in the era of modern sCT in advanced Gastric Cancer  
*P. Piso (Regensburg)*
- 09.15 | Gastrectomy after response to intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis  
*T. Fukagawa (Tokyo)*
- 09.25 | HIPEC for Metastatic Gastric Cancer: Moving the Needle Towards 3-Year Survival  
*N. Bhutiani (Houston)*
- 09.35 | Combined intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis: 16-year experience in Japan  
*Y. Tsuji (Sapporo)*
- 09.45 | Role of peritoneal CEA and CA 19-9 in the detection of peritoneal metastases in gastric adenocarcinoma  
*T. E. Grotz (Rochester)*
- 09.55 | The role of neoadjuvant intra peritoneal systemic (NIPS) chemotherapy in patients with gastric cancer and synchronous peritoneal metastases: results of a western study  
*D. Biacchi (Rome)*
- 10.05 | The effects of HIPEC on survival of gastric cancer patients with peritoneal metastasis  
*Y. Yonemura (Osaka)*

10.15 | Clinical Case Discussion  
*J. Esquivel (Lewes)*

10.30 - 11.00 | **Break**

11.00 - 11.20 | **PLENARY LECTURE**  
**EMERGENT TECHNOLOGIES IN HEALTHCARE**  
Chairperson: *M. Gariboldi (Milan)*

**CART-T Cells on solid Tumors: state of the art**  
*R. De Maria (Rome)*

11.20 - 12.25 | **SESSION X | TRAINING & TEACHING ON PSM**  
Chairpersons: *B. Rau (Berlin), S. Gonzalez Moreno (Madrid)*

11.20 | The ESSO Experience  
*S. Gonzalez Moreno (Madrid)*

11.35 | The Singapore Training & Teaching Experience  
*C. Chia Shulyun (Singapore)*

11.50 | The ESSO Teaching on Peritoneal Surface Malignancies  
*B. Rau (Berlin)*

12.05 | Survey ESSO  
*A. Reis (Sao Paulo)*

12.15 | Starting-up HIPEC – short and long-term results in a low-volume center  
*N. Algethami (Malmo)*

12.25 - 13.00 | **Round Table**  
*B. Rau (Berlin), S. Gonzalez Moreno (Madrid)*

Representative Specialization Schools  
General Surgery: *A. Mingoli (Rome)*  
Medical Oncology: *B. Vincenzi (Rome)*  
Gynecology: *V. Chiantera (Palermo)*

13.00 - 13.30 | **PRESENTATION OF THE NEXT PGOI CONGRESS**  
**AWARDS AND CLOSING CEREMONY**





- 11.00 | **Keynote Lecture VII**  
Imaging on Peritoneal Surface Malignancies  
*A. Laghi (Rome)*
- 11.15 | Role of Laparoscopy in patient's selection  
*O. Sgarbura (Montpellier)*
- 11.30 | The Evaluation Performance of Recognition Algorithm of Pathological Images of Pseudomyxoma Peritonei  
*R. Ma (Beijing)*
- 11.40 | The SALzburg PERitoneal SURface CALCulator (SAPESUCA): The first web-based application for peritoneal surface area quantification  
*T. Jäger (Salzburg)*
- 11.50 | Can surgeons predict the extent of abdominal surgery based on MRI findings in CRS-HIPEC candidates with colorectal cancer?  
*M. Lahaye (Amsterdam)*
- 12.00 | Locations of recurrences after CRS-HIPEC for colorectal peritoneal metastases  
*M. Lahaye (Amsterdam)*
- 12.10 | Variations in recording the surgical, radiological and pathological PCI at experienced peritoneal malignancy centers across the world- a report from the PRECINCT study  
*A. Bhatt (Ahmedabad)*
- 12.20 | Radiological prediction of the pathological peritoneal cancer index (pPCI) - is it tumor agnostic? Results from phase 1 of the prospective, observational, multi-center, PRECINCT study  
*L. Villeneuve (Lyon)*
- 12.30 | Exploratory laparoscopy for peritoneal disease performed in primary care centers: should standardization of operative reports be improved?  
*I. Sourrouille (Villejuif)*
- 12.40 | A prediction model to refine the timing to perform an early second look laparoscopic exploration at high-risk for early peritoneal metastasis recurrence in colon cancer patients  
*M. Pocard (Paris)*
- 12.50 | Clinical Case Discussion  
*F. Iafrate (Rome)*

- 14.30 | Keynote Lecture VIII  
PIPAC: State of the art  
*M. Alyami (Najran)*
- 14.45 | Patient-reported outcomes during first-line palliative systemic therapy alternated with Pressurized Intraperitoneal Aerosol Chemotherapy for unresectable colorectal peritoneal metastases: a single-arm phase II trial (CRC-PIPAC-II)  
*V. van de Vlasakker (Eindhoven)*
- 14.55 | PIPAC: Cost-effectiveness in a high-volume centre  
*A. Di Giorgio (Rome)*
- 15.05 | PIPAC and systemic chemotherapy vs chemotherapy alone in the treatment of peritoneal recurrence from Gastric Cancer  
*F. Casella (Verona)*
- 15.15 | Is there a role for PIPAC in the neoadjuvant treatment of Gastric Cancer?  
*G. De Manzoni (Verona)*
- 15.25 | Feasibility and safety profile of high-dose oxaliplatin-based PIPAC (120mg/m<sup>2</sup>) in the treatment of advanced peritoneal metastatic disease: MINOS multicenter study  
*O. Sgarbura (Montpellier)*
- 15.35 | Preliminary results of electrostatic precipitation pressurized intraperitoneal aerosol chemotherapy (ePIPAC)  
*R. Orgad (Lyon)*
- 15.45 | PIPAC nebulizer after ten years' experience: devices on the market, state of the art and experts' suggestion on how to improve efficacy of the future devices  
*M. Vaira (Torino)*
- 15.55 | Predictors of Completion of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Standard Treatment Protocol: A Retrospective Cohort Study  
*M. Aulicino (Rome)*

---

16.05 - 16.30 | Break

---

11.00 - 12.00 | SESSION III-P | ORAL ABSTRACT  
 NURSES MANAGEMENT OF PERITONEAL SURFACE MALIGNANCIES  
 Chairpersons: *A. Sommariva (Padua), P. Lippolis (Pisa)*

- 11.00 | Personalising care for patients with peritoneal malignancy: Implementation of a treatment folder following cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC)  
*V. Evans (Basingstoke)*
- 11.10 | Inguinal or genital necrosis: A little known adverse effect of Mitomycin-c in HIPEC technique  
*I. Manzanedo (Madrid)*
- 11.20 | ePROMS: An electronic patient related outcome measure service to improve peritoneal tumour patient outcomes  
*R. Halstead (Manchester)*
- 11.30 | A Multidisciplinary Approach to improving outcomes in patients with High Output Stomas following Peritoneal Malignancy Surgery  
*M. Carrol (Sydney)*
- 11.40 | Barthel Index as an indicator of hospital outcome after cytoreductive surgery and HIPEC in patients with ovarian peritoneal metastases  
*A. Gallo (Padua)*
- 11.50 | Perfusion instability in hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery (CRS). The validity of a problem-solving flowchart  
*C. Soligo (Padua)*

12.00 - 13.00 | SESSION IV-P | ORAL ABSTRACT  
 TECHNIQUE ADVANCEMENT ON CRS-HIPEC  
 Chairperson: *A. Sardi (Baltimore), J. Spiliotis (Athens)*

- 12.00 | Follow-up for more than 10 years of patients with peritoneal metastases (PM) treated with cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC) in a specialized unit  
*P. Bretcha Boix (Torrevieja)*
- 12.15 | Influence of type and number of drains used during perfusion in “closed abdomen” HIPEC – an animal study  
*A. K. Martensen (Aarhus)*
- 12.25 | Impact of hyperthermic intraperitoneal chemotherapy (HIPEC) with open or closed abdomen techniques on cisplatin pharmacokinetics  
*M. Lambert (Toulouse)*
- 12.35 | How to minimize post operative adhesions after CRS HIPEC  
*S. Kusamura (Milano)*
- 12.45 | Retrograde (“Down-to-up”) Pelvic Cytoreduction Technique for Panpelvic Carcinomatosis  
*B. Manoglu (Izmir)*

- 12.55 | Multicentric study of multiple reiterative surgical cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases of pseudomyxoma peritone  
*E. Pasqual (Udine)*

13.00 - 14.00 | **Lunch - Poster Viewing and Discussion**

14.30 - 16.00 | **SESSION V-P | ORAL ABSTRACT  
PERIOPERATIVE CARE**  
Chairpersons: *D. Baratti (Milan), R. Gelmini (Modena)*

- 14.30 | **Keynote Lecture X**  
Complexity of perioperative care in patients with PSM  
*B. Rau (Berlin)*
- 14.45 | ERAS on PSM treatment  
*M. Hübner (Lausanne)*
- 15.00 | Surgical Emergencies in Patients with Peritoneal Carcinomatosis: the survey  
*P. Fugazzola (Pavia)*
- 15.10 | Predicting postoperative complications after CRS+HIPEC  
*L. Martin (Las Palmas)*
- 15.20 | CRS HIPEC in the elderly: a difficult balance between feasibility and expected results  
*A. Nissan (Tel Aviv)*
- 15.30 | Implementation and impact of CRS specific, 3-tiered enhanced recovery after surgery protocol in high volume PSM centre  
*L. Bijelic (Barcelona)*
- 15.40 | Failure-to-Rescue (FTR) in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Sharing Our Long-term Institutional Experience Striving for Optimal Quality of Care  
*N. Qisti Fathi (Putrajaya)*
- 15.50 | Perioperative management of patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a prospective observational study  
*G. Fallabrino (Milan)*
- 15.50 | Clinical Case Discussion  
*P. Bretcha (Torrevieja)*

16.00 - 16.30 | **Break**



- 09.00 | **Keynote Lecture XI**  
Laparoscopic CRS HIPEC: Indications and Limits  
*D. Cortés Guiral (Madrid)*
- 09.15 | Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: update from the international PSOGI registry  
*A. Arjona Sanchez (Cordoba)*
- 09.25 | Outcomes of Minimal access cytoreductive surgery (M-CRS) and HIPEC/EPIC vs Open cytoreductive surgery (O-CRS) and HIPEC/EPIC in patients with Peritoneal Surface Malignancies: A Meta-analysis  
*A. Pawar (Ahmedabad)*
- 09.35 | Laparoscopic cytoreductive surgery and HIPEC: early experience in a referral hospital  
*S. Valverde (Barcelona)*
- 09.45 | Initial experience in laparoscopic peritonectomy and HIPEC for the treatment of peritoneal metastasis in a newly establish center  
*M. Alyami (Najran)*
- 09.55 | Laparoscopic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Limited Peritoneal Surface Malignancies: An Early Experience  
*L. Phelan (Birmingham)*
- 10.05 | Robotic Assisted CRS-HIPEC  
*M. Alyami (Najran)*
- 10.15 | LPS/OPEN CRS HIPEC: evolution of a complex technique in South America  
*R. Seitenfus (Porto Alegre)*
- 10.25 | Clinical Case Discussion  
*P. Cascales (Murcia)*

---

10.35 - 11.00 | **Break**

---

## Poster Viewing and Discussion

### OCTOBER 4<sup>th</sup> LUNCH TIME 13.00-14.00

TREATMENT AND PREVENTION OF PERITONEAL METASTASES FROM COLORECTAL CANCER (P01 - P58)

Maurizio Cardi (*Roma*) - Dario Baratti (*Milano*)

APPENDICEAL NEOPLASMS AND MANAGEMENT OF PSEUDOMYXOMA PERITONEI (P59 - P120)

Sara O'Dwyer (*Manchester*) - Kjersti Flatmark (*Oslo*)

CLINICAL TRIALS AND REGISTRIES (P121 - P153)

Marcello Guaglio (*Milano*)

DIAGNOSIS AND STAGING ON PERITONEAL SURFACE MALIGNANCIES (P154 - P171)

Franco Iafrate (*Roma*)

PIPAC (P172-P192)

Marco Vaira (*Torino*)

NURSES MANAGEMENT OF PERITONEAL SURFACE MALIGNANCIES (P193 - P196)

Antonio Sommariva (*Padova*)

MANAGEMENT OF PERITONEAL MESOTHELIOMA (P197 - P203)

Yan Li (*Beijing*)

### OCTOBER 5<sup>th</sup> LUNCH TIME 13.00-14.00

TREATMENT OF PERITONEAL METASTASES OF OVARIAN CANCER (P204 - P233)

S.P. Somashekhar (*Bangalore*) - N. Bakrin (*Lyon*)

BASIC RESEARCH (P234 - P278)

Manuela Gariboldi (*Milano*) - Marc Pocard (*Paris*)

PERIOPERATIVE CARE (P279 - P328)

Aviran Nissan (*Telaviv*) - Massimo Framarini (*Forli*)

TREATMENT AND PREVENTION OF PERITONEAL METASTASES FROM GASTRIC CANCER (P329 - 347)

Franco De Cian (*Genova*)

LAPAROSCOPIC CRS HIPEC (P348 - P411)

Rea Lo Dico (*Rome*) - Alvaro Arjona Sanchez (*Cordoba*)

TRAINING & TACHING ON PSM (P412 - P416)

Andreas Brandl (*Heidelberg*)

## TREATMENT AND PREVENTION OF PERITONEAL METASTASES FROM COLORECTAL CANCER

Chairpersons: *Maurizio Cardì (Roma) - Dario Baratti (Milano)*

### **P01 - Prospective Comparative Analysis of Total Versus Involved Field Parietal Peritonectomy During Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) for Peritoneal Surface Malignancies from Colorectal Cancer**

*P. Darshan, S. P. Somashekar, K. R. Ashwin, Y. Ramya, G. Girish, B. Uday, K. Aggarwal, C. Rohit Kumar  
Karnataka (India)*

### **P02 - Survival prognostic factors in colorectal cancer patients affected by peritoneal carcinomatosis: a single western center experience**

*G. Di Lieto, F. Di Schiena, N. Natalizi, E. Rosati, L. Graziosi, A. Donini  
Perugia (Italy)*

### **P03 - Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Carcinomatosis From Recurrent Rectal Cancer: A Case Report**

*S. García, F. A. De Sá Ribeiro  
Rio de Janeiro (Brasil)*

### **P04 - Factors influencing cure in patients undergoing CRS and HIPEC for peritoneal disease from appendiceal and colorectal cancer.**

*J. Bouchard, T. Araj, L. Hudon, P. Dubé, P. Drolet, L. Sideris, M. L. Soucisse  
Montréal QC (Canada)*

### **P05 - Developing a Core Outcome Set for Cytoreductive Surgery for Colorectal Cancer with Peritoneal Metastasis**

*P. Raichurkar, K. Brown, N. Ansari, C. Koh, N. Ahmadi, D. Steffens  
Sydney (Australia)*

### **P06 - Comparing two types of intraperitoneal chemotherapy for peritoneal metastasis from colorectal cancer and appendiceal neoplasm using an inverse probability of treatment weighting**

*Sujin Kang, Soo Yeun Park, Sang Gyu Kwak, An Na Seo, Jun Seok Park, Hye Jin Kim, Seung Ho Song, Min Hye Jeong, Gyu-Seog Choi  
Daegu (Republic of Korea)*

### **P09 - Oncological Outcomes after Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Synchronous versus Metachronous Colorectal Peritoneal Metastases: a retrospective, pragmatic, observational study.**

*I. Aguirre-Allende, F. Pereira-Pérez, I. Manzanedo-Romero, P. Fernandez-Briones, M. Muñoz-Martín, Á. Serrano-Moral, E. Perez-Viejo  
Gipuzkoa, Madrid (Spain)*

### **P10 - Short-term outcome of hyperthermic intraperitoneal chemotherapy in management of colorectal cancer with peritoneal metastasis, Thailand single center experience**

*C. Sirisai, H. Moungtad, W. Anuponganan, K. Timudom, S. Khunpakdee  
Bangkok (Thailand)*

**P11 - Should we exclude patients with peritoneal carcinosis of colorectal origin and high PCI from CRS+HIPEC?**

*P. Fugazzola, A. Moroni, V. Agnoletti, F. Catena, L. Cobianchi, S. Corallo, F. Dal Mas, S. Frassini, M. Maestri, S. Magnone, A. Pagani, P. Pedrazzoli, A. Rigamonti, G. Santandrea, M. Tomasoni, C. Vallicelli, J. Viganò, L. Ansaloni*  
 Pavia, Cesena, Venezia, Bergamo (Italy)

**P12 - Cytoreductive Surgery and Intra-peritoneal Chemotherapy for Peritoneal Metastasis of Colorectal Cancer: Analysis of Prognostic Factors related to Survival.**

*H. Namgung, J., W. Suh, S. Chul Lee, D. Guk Park*  
 Cheonan (Republic of Korea)

**P13 - Survival prognostic factors in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy: A single institution experience**

*S. Nikolic, V. Jokic, M. Kocic, L. Pejnovic*  
 Belgrade (Serbia)

**P14 - Pilot Study: Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal cancers at high risk of developing peritoneal metastases in a tertiary Asian centre**

*Seo Chin Jin, Grace Tan Hwei Ching, Johnny Ong Chin-Ann, Jolene Wong Si Min, Nicholas Shannon, Claramae Chia Shulyn, Melissa Teo Ching Ching*  
 Singapore (Republic of Singapore)

**P15 - Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy versus R0 Resection for Resectable Colorectal Cancer with Peritoneal Metastases with Low Peritoneal Cancer Index Score: An Observational Study from Korea and Japan**

*D. Kitaguchi, E. Jung Park, S. Hyuk Baik, S. Sasaki, Y. Tsukada, M. Ito*  
 Chiba, (Japan); Seoul (Korea)

**P16 - Is Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy still beneficial in patients diagnosed with Colorectal Peritoneal Metastasis who underwent Palliative Chemotherapy?**

*Hye Jung Cho, Jong Woo Kim, Woo Ram Kim*  
 Seoul, Seongnam (Republic of Korea)

**P17 - Survival outcome of neoadjuvant chemotherapy in cytoreductive surgery and HIPEC for colorectal cancer with peritoneal metastases**

*M. Sarofim, R. Wijayawardana, N. Ahmadi, S. Barat, D. L Morris*  
 Sydney (Australia)

**P19 - Recurrent Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Colorectal Cancers: Tertiary Single-Center Results**

*P. Özcan, M. Kalın, Ö. Düzgün*  
 Istanbul (Turkey)

**P20 - Cytoreduction with or without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with mitomycin C and Doxorubicin for colorectal peritoneal metastasis – a retrospective data analysis**

*C. Müller, A. Kartik, P. Starlinger, T. Bachleitner-Hofmann, T. E. Grotz*  
 Vienna (Austria)



**P21 - Anastomotic leakage after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a clinical cohort study**

J. Herzberg, M. Acs, S. Yousuf Guraya, Ha. J. Schlitt, H. Honarpisheh, T. Strate, P. Piso Regensburg, Reinbek -(Germany); Sharjah (United Arab Emirates)

**P22 - Quality of life following Cytoreductive Surgery and Hyperthermic Intraperitoneal chemotherapy in patients with Colorectal Peritoneal Metastasis: An international evaluation between Australia and UK**

D.Steffens, N. Ansari, M. J. Solomon, K. McBride, S.Karunaratne, H. Solanki, B. Moran Hampshire (United Kingdom); Sydney (Australia)

**P23 - 30 Years of Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis of Colorectal and Appendiceal Cancer in Austria**

F. Laminger, M. Behanova, Y. Grin, M.Hermann, F. Kober, H. Meisel, S. Roka, C. Koppitsch Vienna (Austria)

**P24 - Predictors for Survival after Cytoreductive Surgery for Colorectal Peritoneal Metastases: A Retrospective Multivariable Cox Regression Analysis**

K. Gabsi, N. D'Souza, N.Ahmadi, N. Ansari, C. Koh, D.Steffens, B.Moran Sydney (Australia)

**P25 - Curative surgical treatment of colorectal peritoneal metastases associated with extraperitoneal metastases – what could we expect?**

D.Steffens, N. Ansari, C. Koh, M. J. Solomon, K. McBride, S.Karunaratne, H. Solanki, B. Moran Villejuif, Paris (France)

**P26 - Impact of the molecular profile in individualized treatment with cytoreduction and hipec for patients with colorectal peritoneal metastases**

I. de Ariño Hervas, I.Aguirre Allende, M. Alkorta Zuloaga, X. Arteaga Martin, M. Angel Medrano Gómez, R. Jimenez-Agüero, A. Beguiristain Gómez, A. P. Riverola Aso, I. Ruiz Montesinos, J.M. Enriquez Navascués. Donostia-San Sebastian (Spain)

**P27 - Correlation between the distribution of colorectal peritoneal metastases in the peritoneal cavity and the mechanism of peritoneal spread – an analysis from the PRECINCT study**

A. Bhatt, V. Kepenekian, D. Baratti, D. Biacchi, N.Benzerdjeb, A. Buseck, I. Bonnefoy, S. Barat, M. Deraco, D. Morris, A. Souadka, M. Alyami, V. Gushchin, N. Shah, G. Adeleke, S. Stanford, V. Mark Samuel, K.Cummins Perry, B. El Khannousi, S. Khouchoua, N. El Bahaoui, U. Sarpel, D. Labow, N. Khajouinejad, S. Troob, F. Mohammad, B. Moran, E. Levine, P. Rousset, L. Villeneuve, P. Sarmmartino, A. Sardi, O. Glehen Lyon (France); Rabat (Morocco); Winston-Salem, Baltimore and New York (USA); Basingstoke (UK); Najran (Saudi Arabia); Sydney (Australia); Rome and Milan (Italy); Ahmedabad (India)

**P28 - Morphological appearance on imaging and the incidence of disease on pathology in patients with colorectal peritoneal metastases undergoing cytoreductive surgery- results from the PRECINCT study**

A. Bhatt, F. Mohammad, D.Baratti, D. Biacchi, N. Benzerdjeb, A. Buseck, I. Bonnefoy, S. Barat, M. Deraco, D. Morris, A. Souadka, M. Alyami, V. Gushchin, N. Shah, G. Adeleke, S. Stanford, V. Mark Samuel, K. Cummins Perry, B. El Khannousi, S. Khouchoua, N. El Bahaoui, U. Sarpel, D. Labow, N. Khajouinejad, S.Troob, V. Kepenekian, B. Moran, E.Levine, P. Rousset, L. Villeneuve, P.Sarmmartino, A.Sardi, O. Glehen Lyon (France); Rabat (Morocco); Winston-Salem, Baltimore and New York (USA); Basingstoke (UK); Najran (Saudi Arabia); Sydney(Australia); Rome and Milan (Italy); Ahmedabad (India)

**P29 - Impact of mucinous component of colorectal cancers with peritoneal metastasis treated by Cytoreductive surgery and Hyperthermic Intra-Peritoneal Chemotherapy – A retrospective bicentric comparative study with propensity score**

*E. Traversari, A. Kefleyesus, M. Dazza, J. Peron, N. Benzerdjeb, P. Rousset, O. Turrini, O. Glehen, V. Kepenekian*

*Pierre Bénite, Marseille, (France)*

**P30 - Predictive Factors of Peritoneal Metastasis of Colorectal Cancer**

*G. B. Alghbewi, N. Alsheikh, A. Aljulayfi, F. Aljehaiman, A. Alsubaie, A. Alrasheed, N. Alzahrani Riyadh (Saudi Arabia)*

**P31 - Prognostic factors for early recurrence after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis of colorectal origin in the molecular markers era.**

*A. Alsourani, P.Lozano Lominchar, B. Castro Catalán, M. F. Ballón Bardo, S. Pérez Ajates, N. Palencia Garcia, W. Vásquez Jiménez, L. González Bayón Madrid (Spain)*

**P32 - Comparative study of CRS and HIPEC with or without liver resection: Propensity-score matched outcomes in 110 patients**

*G. Han Lee, F. Ansari, K. Chandrakumaran, A. Tzivanakis, F. Mohamed, T. Cecil, S. Dayal, B. Moran Hampshire (UK)*

**P33 - The CEA/PCI ratio is a superior prognosticator than the mCOREP score for colorectal cancer patients with peritoneal metastasis undergoing Cytoreductive Surgery with or without HIPEC**

*P. Anthony, S. Barat, N. Ahmadi, D. Morris Sydney (Australia)*

**P34 - Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Aotearoa New Zealand: a retrospective review.**

*J. Lim, R. Qin, J. Ly, J. Fischer, N. Smith, M. Karalus, L. Wu, R. van Dalen, S. Lolohea Hamilton (New Zealand)*

**P35 - Cytoreductive surgery and Hyperthermic intraperitoneal chemotherapy for peritoneal metastasis originated from colorectal cancer: long-term follow-up results at a single institution in Turkey**

*B. Canbay Torun, E. Sobutay, O. Eren Akbulut, S. Yılmaz, C. Sezgin, S. Saglam, Y. Yonemura, E. Canbay, G. Sokak Turkey (Istanbul)*

**P36 - Outcomes following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: analysis of 1138 consecutive patients from the UK&I Colorectal Peritoneal Metastases Registry**

*J. Wild, L. Malcolmson, F. Polignano, J. Mulsow, A. Renehan, F. Mohamed Hampshire Hospital, Manchester, Dundee (UK); Dublin (Ireland)*

**P39 - Differences in patient- and tumor characteristics, treatment and survival between patients with screen-detected and clinically detected synchronous colorectal peritoneal metastases**

*A. Rijken, M.A.G. Elferink, D. Boerma, A. Brandt-Kerkhof, P.R. de Reuver, J.B. Tuynman, N.F.M. Kok, P.H.J. Hemmer, W.M.U. van Grevenstein, C. Huysentruyt, F.N. van Erning, I.H.J.T. de Hingh Eindhoven, Utrecht, Groningen, Amsterdam, Nijmegen (Netherlands)*

**P40 - Study the past to define the future: Actions following previous research led to elimination of disparities in treatment of patients with colorectal peritoneal metastases**  
 R.G.F.M. van der Ven, T.B.M. van den Heuvel, F. N. van Erning, K. P.B. Rovers, S. W. Nienhuijs, I. H.J.T. de Hingh  
 Maastricht, Eindhoven (The Netherlands).

**P41 - Extensive Colorectal Peritoneal Metastasis: Can Aggressive Curative Resection Help?**  
 S. Alshammari, M. Alturaiki, Y. Alkhayyal, H. Helmi, T. Bin Traiki  
 Riyadh (Saudi Arabia)

**P42 - Reduced expression of drug transporter SLC7A6 – a possible explanation for failure of mitomycin C-based HIPEC in BRAF-mutated peritoneal metastases from colorectal cancer.**  
 C. Lund-Andersen, A. Torgunrud, C. Kanduri, V. J Dagenborg, I. S. Frøysnes, M. Larsen, B. Davidson, S. G. Larsen, K. Flatmark  
 Oslo (Norway)

**P43 - A prospective cohort of patients with colorectal peritoneal metastases treated with CRS-HIPEC: development and first results of the Dutch HIPEC quality registry.**  
 F. N. van Erning, T. B.M. van den Heuvel, F. Sijtsma, D. Boerma, A. R.M. Brandt-Kerkhof, A. J.A. Bremers, E.B. van Duyn, W. M.U. van Grevenstein, P. H.J. Hemmer, N. F.M. Kok, E. V.E. Madsen, P. R. de Reuver, R. J. Wiezer, A. J. Witkamp, S. W. Nienhuijs, F. Poelmann, J. B. Tuijnman, L. Been, K. P.B. Rovers, I. H.J.T. de Hingh  
 Maastricht, Eindhoven, Amsterdam, Gronigen, Nieuwegein, Rotterdam, Enschede (Netherlands)

**P44 - Long-term survival after CytoReductive Surgery and Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) for carcinomatosis from colorectal cancer: a single centre experience**  
 S. Magnone, A. Rigamonti, A. Allegri, M. Pisano, E. Poiasina, S. Mosconi, B. Merelli Barbara, A. Lucianetti  
 Bergamo (Italy)

**P45 - Risk factors for decreased survival in 519 patients with colorectal peritoneal metastases treated by cytoreductive surgery and HIPEC**  
 N. Allievi, M. Sidhom, M.Vasanth Samuel, I. Panagiotopoulou, A. Tzivanakis, S.Dayal, T. Cecil, F. Mohamed, B. Moran  
 Hampshire (UK)

**P48- Cytoreductive surgery ± hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases only from BRAF V600E mutated colorectal cancer. A retrospective study.**  
 J. Fawaz, R.Kaci, B. Malgras T. Andres, M. Pocard, R. Lo Dico  
 Paris (France)

**P49 - Cytoreductive surgery (CRS) and HIPEC for peritoneal metastasis of colorectal cancer (PMCR): use of mitomycin (MMC) decrease postoperative morbi-mortality by 2.**  
 C. Houlze-Laroye, O. Glehen, E. Gayat, J. Tuech, M. Pocard, J. Delhorme, C. Brigand, G. Piessen, C. Eveno  
 Lille, Strasbourg, Quillins (France)

**P50 - Transitioning from open to close HIPEC: comparing outcomes in patients with peritoneal involvement of colorectal cancer.**  
 M.J. Madeira-Cardoso, M. Marques, P. Pinto, C. Baía, A. Sousa, F. Sousa, M. Fernandes, J. Abreu de Sousa  
 Porto (Portugal)

**P52 - Novel radiopharmaceutical for intraperitoneal treatment of peritoneal metastasis from colorectal and ovarian cancer after complete surgical resection**

S. Westrøm, T. Bjørnlund Bønsdorff, A. Aksnes, K. Myren  
Oslo (Norway)

**P53 - The influence of the introduction of a nationwide screening program for colorectal cancer on the proportion of CRS-HIPEC in patients with isolated peritoneal metastases**

L. J.K. Galanos, A. Rijken, M. A.G. Elferink, C.Huysentruit, K.Kuhlmann, N. F.M. Kok, F. N. van Erning, I. H.J.T. de Hingh  
Amsterdam, Utrecht, Eindhoven (Netherlands)

**P54 - Early outcomes of a new colorectal peritoneal metastases service for Wales**

J. Parker, M. Shinkwin, J.Torkington, J. Horwood, L. Davies  
Cardiff (UK)

**P55 - Systemic therapy for colorectal peritoneal metastasis: tumor sidedness predicts survival benefit for neoadjuvant triplet therapy**

E. Breuer, Z. Li, I.Bonnefoy, L. Russo, L. Villeneuve, G. Passot, V. Kepenekian, O. Glehen, K. Lehmann  
Zurich (Switzerland); Villeurbanne (France)

**P56 - Interval second look surgery and HIPEC in patients at risk of colorectal peritoneal metastases: report of a monocentric experience.**

M. Tomassi, A. Kefleyesus, L. Villeneuve, I. Bonnefoy, N. Benzerdjeb, O. Glehen, V. Kepenekian  
Pierre-Bénite, Oullins (France); Lausanne (Switzerland)

**P57 - Results of systemic therapy and CRS+HIPEC procedures in colorectal cancer's peritoneal dissemination in Wroclaw Comprehensive Cancer Center patients in 2014-2023**

K. Szewczyk, M. Bebenek  
Wroclaw (Poland)

**P58 - Complete Cytoreduction and HIPEC for Peritoneal Carcinomatosis in Colon Cancer in Nuestra Señora de la Candelaria University Hospital: Morbidity, Mortality, and Survival Analysis**

M. Rojas Estevez, J. Abellán Fernández, V. Concepción Martín, C. Díaz López, R. Hareh Gianchandani Moorjani, R. Orti Rodríguez, J. Manuel Sánchez González, J. Miguel del Pino Monzón, E. Moneva Arce, M. Ángel Barrera Gómez  
Santa Cruz of Tenerife (Spain)

**APPENDICEAL NEOPLASMS AND MANAGEMENT OF PSEUDOMYXOMA PERITONEI**

**Chairpersons:** Sara O'Dwyer (Manchester) - Kjersti Flatmark (Oslo)

**P59 - What is the risk of peritoneal recurrence from a non-perforated low grade appendiceal mucinous neoplasms? 15 years of experience from a tertiary referral peritoneal malignancy service**

C. Lakmal, C. Tan, S. O'Dwyer, R. Kochher, B. Chakrabarty, O. Aziz, H. Clouston, M. Wilson, P. Sutton, J. Wild, C.R. Selvasekar, A.G. Renehan  
Manchester (UK)

**P60 - Appendiceal Neoplasms Continue to Increase in Incidence – A Contemporary Population-Based Analysis**

S. J. Concors, K. Beaty, N. Bhutiani, Y. Song, B. Helmink, C. Scally, P. Mansfield, J. Maxwell, M. White, K. Fournier  
Houston (USA)

**P61 - Survival outcomes of peritoneal metastases originating from High Grade Appendiceal cancers with diaphragmatic involvement after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy**

D. L. Morris, T. Williams, R. Wijayawardana, S. Barat  
Kogarah (Australia)

**P62 - Salvageable cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for low-grade appendiceal mucinous tumors with early and limited disease after completely removed**

C. Wang, R. Ma  
Beijing (China)

**P63 - Combined use of preoperative ultrasound and tumor markers: better distinguish Low-Grade Appendiceal Mucinous Neoplasm from acute appendicitis**

X. Han, R. Ma, L. Liang, H. Bin Xu  
Beijing (China)

**P64 - Travel Distance Does Not Affect Overall Survival in Patients with Appendiceal Adenocarcinoma Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy**

J. Sadjadi, L. Luo, B. Fahy, V. Rai, S. Popek, L. Baste McKean, A. Greenbaum  
New Mexico (USA)

**P65 - Follow up of low grade appendiceal mucinous neoplasms and the risk of progression to Pseudomyxoma Peritonei**

V. Mark Samuel, N. Allievi, K. Chandrakumaran, A. Tzivanakis, S. Dayal, T. Cecil, F. Mohamed, B. Moran  
Basingstoke (UK)

**P66 - The comparison of carcinoembryonic antigen levels between portal and peripheral blood in patients with appendiceal adenocarcinoma (copper) trial**

A. Cristaudo, D. L. Morris, M. Breakeit, N. Ahmadi, S. Barat  
New South Wales (Australia)

**P68 - Comparing survival outcomes and impact of EPIC in patients undergoing CRS/HIPEC for mucinous appendiceal neoplasm**

M. Mercado, R. Shamavonian, E. Cheng, N. Ahmadi, D. L. Morris  
Kogarah, Sydney (Australia)

**P69 - The role of systemic chemotherapy in appendix adenocarcinoma.**

J. Barriuso, M.C. Strach, B. Chakrabarty, R. T. Nagaraju, S. Mullamitha, M. Braun, O. Aziz, S.T O'Dwyer  
Manchester (UK)

**P70 - Intestinal metaplasia of appendiceal and terminal ileal endometriosis with widespread dissecting acellular mucin: a challenging case mimicking appendiceal mucinous neoplasia with peritoneal disease.**

S. Evans, H. Clouston, R. Connolly, B. Chakrabarty  
Manchester (UK)

**P71 - Risk factors for peritoneal metastases in perforated appendiceal adenocarcinoma**  
*D. Madonia, P. Cashin, W. Graf, L. Ghanipour*  
 Uppsala (Sweden)

**P72 - Combined total gastrectomy and total colectomy to obtain CC0 cytoreduction in a patient with pseudomyxoma peritonei**  
*E. Zanella Cordeiro, R. Baretta, M. Sperotto Cecon, J. Marcelino Alves*  
 Santa Catarina (Brazil)

**P73 - Prior Surgery (PS) a potential modifiable risk factor in Appendiceal Cancer Peritoneal Metastasis (ACPM) contributing to Genitourinary (GU) Implantation and outcome**  
*A.Tu, C. Zhang, D.D. Hegeholtz, S. P. McDermott, I. Igbini, M. Craig, V. Shostrom, J.M. Foster*  
 Nebraska (USA)

**P74 - Benign mimics of low grade appendiceal mucinous neoplasms – 10-years' experience from a peritoneal oncology referral centre**  
*S. Evans, L. Platt, O. Aziz, S. T O'Dwyer, B. Chakrabarty*  
 Manchester (UK)

**P75 - Active surveillance for low-grade appendiceal mucinous neoplasm (LAMN)**  
*C. Mouawad, A. Bardier, M. Wagner, S. Doat, D. Djelil, J. Fawaz, M. Pocard,*  
 Paris (France)

**P76 - Laparoscopic cytoreductive surgery and HIPEC in the treatment of mucinous appendicular neoplasia with low peritoneal dissemination**  
*E. Zanella Cordeiro, R. Baretta, M. Sperotto Cecon, J. Marcelino Alves*  
 Santa Caterina (Brazil)

**P79 - Peritoneal spread exceeds nodal involvement in high-grade appendiceal neoplasms with no detectable radiological disease undergoing prophylactic cytoreduction and HIPEC: 29 year single centre analysis**  
*V. Sharma, S. Reddy Satti, R. Singh, A. Tzivanakis, S. Dayal, F. Mohamed, B. Moran, T. Cecil*  
 Basingstoke (UK)

**P80 - Exploring Treatment Delays rendering Appendiceal Mucinous Tumors Inoperable in Pakistan**  
*R. Sayyed, M. Faraz Khan, A. Brandl, S. Asad Abbas Jafri, M. Tayyab ul Hassan Siddiqui, B.Ayub, M. Shamim Qureshi*  
 Karachi (Pakistan); Berlin (Germany); Dublin (Ireland)

**P81 - Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (Hipec) for appendix mucinous adenocarcinoma: Single institution experience of 43 Cases**  
*C. Muzi, L. Castro*  
 Rio de Janeiro (Brazil)

**P82 - Patients with localized appendiceal adenocarcinoma have excellent outcome after surgical resection**  
*M.M. Fanaeian, M.Yousef, A.Yousef, M. Zeineddine, K.A. Beaty, P.F. Mansfield, K. F. Fournier, C. Scally, B. Helmink, J.Paul Shen*  
 Texas (USA)

**P83 - A validation French cohort of the new WHO 2019 classification for appendiceal cancer: importance of histopathology and tertiary referral center management to improve the prognosis of patients**  
*B. Valenzuela-Mendez, O. Sgarbura, L. Khellaf, S. Carrere, A. Bouillin, T. Mazard, S. Nougaret, F. Quenet*  
 Montpellier (France)

**P84 - VENICE 5 - Appendiceal Mucocellis - A literature review about surgery approach and a south brazilian expert opinion about it.**

*R. Seitenfus, C. Cereser, E. Dipp, A. Carolina Fleig, L. Immich, E. Cristina Moreira de Lima, R. Rebelatto, L. Rotta, J. Abarca, J. Moreno Cando  
Rio Grande do Sul (Brazil)*

**P85 - Image-Processing-Based Quantitative Analysis of Ki-67 Has Better Prediction Performance than Manual Counting in Pseudomyxoma Peritonei from Appendix**

*Ru Ma, Yu-Lin Lin, Yan-Dong Su, Feng-Cai Yan, Zhao Li, Ying Gao, Yan Li  
Beijing (China)*

**P87 - Etiological Analysis of Infection after CRS+HIPEC in Patients with PMP**

*Rui Yang, Xin Zhao, Yu-Bin Fu, Yu-Lin Lin, Ru Ma, Yan-Dong Su, He-Liang Wu, Xin-Li Liang, Yan Li  
Beijing (China)*

**P88 - Ultrasound-guided day-case wide-bore percutaneous mucin aspiration in advanced pseudomyxoma peritonei**

*P. Borg, H. Hoi-Lam, D. Mullan, O. Aziz, H. U. Laasch  
Leeds (UK)*

**P89 - Clinical value of hysterectomy and bilateral salpingo-ovariectomy in women with pseudomyxoma peritonei of an appendiceal origin**

*Fengxian Fu, Xulan Ma, Yiyang Lu, Hongbin Xu, Ruiqing Ma  
Beijing (China)*

**P90 - Preoperative intraperitoneal chemotherapy for peritoneal carcinomatosis of appendiceal origin**

*T. Kitai, S. Wakama, S.Sako, Y. Liu MD, Y. Yonemura  
Kishiwada (Japan)*

**P91 - CRS+HIPEC for pseudomyxoma peritonei with high tumor burden**

*T. Kitai, K. Okada, K. Yamanaka, Y. Yonemura  
Kishiwada, Amagasaki (Japan)*

**P92 - Impact of combination chemotherapy in peritoneal Pseudomyxoma Peritonei Hyperthermic Intraperitoneal Chemotherapy (HIPEC): a RENAPE study**

*B. Malgras, C. Hobeika, A. Cécile Ezanno, A. Aimé, M. Pocard  
Paris (France)*

**P93 - Left Lateral Liver Lobectomy Facilitates Safe Cytoreduction in the Left Retrohepatic Space in a Patient with Low-grade Mucinous Carcinomatosis**

*V. Gushchin, M. Caitlin King, K. Pawlikowski, A. Sardi  
Baltimore (USA)*

**P94 - Hyperthermic intraperitoneal chemotherapy may benefit for unresectable pseudomyxoma peritonei who underwent maximal tumor debulking surgery**

*P. Zhang  
Beijing, China*

**P95 - Risk factors of postoperative complications in elderly patients with pseudomyxoma peritonei**

*Xiwen Fan, Guanjun Shi, Chong Wang, Hongbin Xu, Ruiqing Ma  
Beijing, China*

**P96 - Efficacy and prognosis analysis of 600 cases of PMP underwent CRS+HIPEC: A single-center retrospective study.**

Rui Yang, Yu-Bin Fu, Xin Zhao, Xin-Bao Li, Yu-Lin Lin, Ru Ma, Yan-Dong Su, He-Liang Wu, Xin-Li Liang, Yan Li  
Beijing, China

**P97 - Diagnostic and therapeutic algorithm for appendiceal tumours and pseudomyxoma peritonei: a consensus of the peritoneal malignancies oncoteam of the Italian Society of Surgical Oncology (SICO).**

M. Vaira, M. Robella, M. Guaglio, P. Berchiolla, A. Sommariva, M. Valle, E. Pasqual, F. Roviello, M. Framarini, G. Fiorentini, P. Sammartino, A. Ilari Civit, A. Di Giorgio, L. Ansaloni, M. Deraco  
Milano, Pavia, Roma, Candiolo, Torino, Udine, Padova, Ravenna, Forlì, Siena (Italy)

**P98 - Long-term quality of life following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendiceal origin**

V. Kung, M. Delisle, S. Alves, F. Mohamed, T. Cecil, B. Moran  
Ontario (Canada); Basingstoke (UK)

**P99 - Effect of preoperative systematic chemotherapy on postoperative survival in patients with Peritoneal Pseudomyxoma—A single center retrospective PSM-IPTW study**

Zhang Ying, Li Yan  
Benijing (China)

**P100 - Does weight influence post-operative outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei?**

A. Yates, J. Muller, C. Owens, K. Chandrakumar, V. Mark Samuel, A. Tzivanakis, F. Mohamed, T. Cecil, B. Moran  
Basingstoke (UK)

**P101 - Platinum-based versus mitomycin hyperthermic intraperitoneal chemotherapy in cytoreductive surgery treatment for pseudomyxoma peritonei – a Swedish national peritoneal oncology group study**

N. Farrokhnia, M. Enblad, V. Verwaal, G. Jansson Palmer, J. Tranberg, W. Graf, H. Cashin Peter  
Uppsala, Malmo, Stockholm, Gothenburg (Sweden)

**P102 - The pattern, predictors, and management of recurrence following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal pseudomyxoma peritonei in Aotearoa, New Zealand**

J. Lim, R. Qin, J. Ly, J. Fischer, N. Smith, M. Karalus, L. Wu, R. van Dalen, S. Lolohea  
Hamilton (New Zealand)

**P103 - Peritoneal recurrence following appendectomy for perforated low-grade mucinous appendiceal neoplasms: evaluation of a dual strategy of watch-and-wait and risk-reducing cytoreductive surgery and heated intraperitoneal chemotherapy**

J. Wild, B. Aljalbneh, W. Kyle Wong, L. Malcolmsen, P. Sutton, R. Fish, H. Clouston, C. Selvasekar, A. Renehan, M. Wilson, S. O'Dwyer, B. Chakrabarty, O. Aziz  
Manchester, Belfast (UK); Amman (Jordan)

**P104 - Is cytoreductive surgery without HIPEC (CRS) a valid strategy for managing patients with massive pseudomyxoma peritonei (PMP)?**

S. Ahrendt, R. Torphy, B. Mungo  
Aurora (USA)



**P105 - Perihepatic tumor burden in pseudomyxoma peritonei (PMP) predicts complexity of CRS and risk of recurrence but not resectability or survival**

*S. Ahrendt, B. Mungo, M. Markese, R. Torphy  
Aurora (USA)*

**P106 - A liquid biopsy approach for the characterization of pharmacokinetics and pharmacodynamics protein targets in exosomes from Pseudomyxoma peritonei patients**

*A.M. Vasilogianni, B.Achour, O. Aziz, J. Barber, A.Rostami-Hodjegan, C. Demonacos  
Manchester (UK)*

**P107 - Impact of preoperative sarcopenia on the short-term outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for Pseudomyxoma peritonei**

*Y. Hayashi, Y. Gohda, S. Okamoto, K. Aso, N. Kokudo, H. Yano  
Tokyo (Japan)*

**P108 - The Management of Extensive Pseudomyxoma Peritonei: Technical Considerations**

*A. Sardi  
Baltimore (USA)*

**P109 - Solution to avoid right hemicolectomy in Pseudomyxoma Peritonei: evaluation of predictive factors to identify low grade types preoperatively**

*R. Ghandour, A. Bardier, M.Wagner, B. Malgras, R. Kaci, M. Pocard  
Paris (France)*

**P110 - Excellent long-term outcomes of CRS with gastrectomy to achieve complete cytoreduction for extensive appendiceal pseudomyxoma peritonei – a 26-year experience from a high-volume peritoneal malignancy unit**

*V. Kung, A. C Lord, V. Mark Samuel, F. Di Fabio, A.Tzivanakis, F. Mohamed, S.Dayal, T. Cecil, B. J Moran  
Basingstoke (UK)*

**P111 - Predicting low-grade pseudomyxoma peritonei (PMP) to avoid right colectomy during cytoreductive surgery and HIPEC.**

*R. Gandour, A. Bardier, M. Wagner, Brice Malgras, R. Kaci, M. Pocard  
Paris, St Mande (France)*

**P112 - Urgent CRS and HIPEC for decompensated patients with pseudomyxoma peritonei is associated with increased post-operative morbidity but no increase in mortality: Propensity score matched experience.**

*K. Gunasekare, M. Samuel, A. Yates, K. Chandrakumaran, S. Dayal, F. Mohamed, A. Tzivanakis, T.Cecil, B. Moran  
Basingstoke (UK); Kandy (Sri Lanka)*

**P113 - Two stage surgical management of fragile patients with pseudomixoma peritonei in guadalajara, Mexico.**

*F. Ayala Guillermo, A. Garcia Ramses  
Jalisco (México)*

**P114 - Programmed cell death ligand-1 (PD-L1) expression in Pseudomyxoma peritonei**

*S. Bigolin, G. Zalgelli, A. Scapinello, M.Tonello, P. Pilati, M.L. Calabrò, I. Monia Montagner  
Padova (Italy)*

**P115 - Survival benefits with EPIC in addition to HIPEC for low grade appendiceal neoplasms with pseudomyxoma peritonei: a propensity score matched study**

*R. Hayler, K. Lockhart, S. Barat, N.Ahmadi, N.Alzahrani, W. Liauw, D. Morris  
Sydney (Australia); Riyadh (Kingdom of Saudi Arabia)*

**P116 - The role of 18F-FDG PET in preoperative evaluation of pseudomyxoma peritonei**  
 Y. Gohda, Y. Hayashi, S. Okamoto, N. Kokudo, H. Yano  
 Hampshire (UK), Tokyo (Japan)

**P117 - Better support through better knowledge: a systematic review concerning what we know and do not know about pseudomyxoma peritonei (PMP) patients' QoL**  
 E. Pizzolato, E. Pinto, B. Cavattoni, I. Lazzari, M. Mura, P. Pilati, M. Tonello, A. Sommariva  
 Padova (Italy)

**P118 - Impact of peritoneal metastasis histological grade on prognosis of Pseudomyxoma peritonei arising from appendiceal mucinous neoplasms**  
 A. Hasan, B. Chakrabarty, C. Kearsey, R.T. Nagaraju, M. Wilson, A. Renehan, C. Selvasekar, H. Clouston, J. Wild, P. Sutton, R. Fish, S. T. O'Dwyer, O. Aziz, J. Barriuso  
 Manchester (UK)

**P119 - Histological characters of PMP associated with poor prognosis after complete cytoreductive surgery**  
 S. Takemura, M. Hino, M. Ishida, Y. Mizumoto, N. Takao, Y. Yonemura, R. Kushima  
 Shiga, Kyoto, Osaka (Japan)

**P120 - Intraperitoneal administration of carcinoembryonic antigen-directed CAR-T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer**  
 S. Qian, P. Villarejo-Campos, V. Domínguez-Prieto, D. Dai, L. Qin, Y. Li, I. Guijo Castellano, S. Jiménez Galanes, H. Guadalajara Labajo, M. Garcia-Arranz, D. García-Olmo, M. Jiménez-Fuertes, J. Shen, C. Qian  
 Madrid (Spain); Chongqing (China)

## CLINICAL TRIALS AND REGISTRIES

**Chairperson:** Marcello Guaglio (Milano)

---

**P121 - Fluorescence-guided laparoscopy with hypericin for staging of locally advanced gastric cancer - a pilot trial**  
 C. Yurttas, I. Fischer, K. Thiel, R. Ladurner, I. Königsrainer, P. Horvath, A. Königsrainer, S. Beckert, M.W. Löffler  
 Villingen-Schwenningen, Tübingen (Germany); Feldkirch (Austria)

**P122 - Rationale and Study Design of the KOV-HIPEC-02 trial: a Randomized, Multicenter, Open-label Phase III trial of Hyperthermic Intraperitoneal Chemotherapy in Platinum-Resistant Recurrent Ovarian Cancer**  
 Ji Hyun Kim, Eun-Young Park, Sokbom Kang, Sang-Soo Seo, Sang-Yoon Park, Dae Hoon Jeong, Yoo-Young Lee, Chel Hoon Choi, Tae Joong Kim, Byoung-gie Kim, Jae-Weon Kim, Hyun Hoon Chung, Tae Hun Kim, Taek Sang Lee, Hye Won Jeon, Shin-Wha Lee, Jeong-Yeol Park, Sung Jong Lee, Eun Ji Nam, Jung-Yun Lee, Seob Jeon, Ki Hyung Kim, Hyeongin Ha, Youngbok Ko, San-Hui Lee, Jong Chul Baek, Suk-Joon Chang, Myong Cheol Lim  
 Suwon, Goyang, Busan, Seoul, Korea, Pusan (Korea)

**P127 - Normothermic intraperitoneal chemotherapy – long term (NIPEC-LT) in peritoneal metastases from colorectal cancer – Norwegian feasibility study**  
 M. Adam Goscinski, V. Johansen Dagenborg, A. Holterman, A. Ersryd, P. Wrancicz, K. Flatmark, L. Julsrud, N. Tore Vetthe, Y. Li, S. Gunnar Larsen  
 Oslo (Norway); Beijing (China)

**P128 - Hepatocellular Carcinoma Peritoneal Metastasis: Role of Cytoreductive Surgery and hiperthermic Intraperitoneal Chemotherapy (HIPEC)**

*G. Peppas, J. Spiliotis, D. Farmakis, N. Kopanakis, A. Raptis  
Athens, Thessaloniki, Pireus (Greece)*

**P129 - Role of Early Bedside HIPEC as Adjuvant Treatment in Colorectal Peritoneal Metastasis**

*J. Spiliotis, D. Farmakis, N. Spiliotis Jason, H. Saroyan, D. Vaikos, H. Margari, D. Karachalios  
Thessaloniki, Athens (Greece)*

**P130 - Peritoneal metastasis from cervical cancer CRS+HIPEC**

*J. Spiliotis, N. Kopanakis, C. Iavazzo, I. Noskova, D. Karachalios, H. Margari  
Athens, Thessaloniki, Pireus (Greece)*

**P131 - Breast Cancer Peritoneal Metastasis. Role of CRS+HIPEC"**

*I. Noskova, J. Spiliotis, G. Peppas, G. Dadoudis  
Athens, Thessaloniki (Greece)*

**P132 - Intraperitoneal (IP) lidocaine infusion is an efficient and safe pain treatment for Normothermic Intraperitoneal Chemotherapy - long term (NIPEC-LT) for patients with colorectal cancer carcinomatosis**

*P. Wranicz, A. Holtermann, H. Andersen, K. Erling Juul-Hansen, M. Goscinski  
Oslo (Norway)*

**P133 - A Phase III Randomized Controlled Trial in Primary Stage Three and Four Ovarian Cancer After Interval Cytoreductive Surgery (FOCUS)**

*Ji Hyun Kim, Boram Park, Jae Bong Kim, Jung-Yun Lee, Suk-Joon Chang, Yoo-Young Lee, Daegy Hong, Hyun Woong Cho, Jae-Yun Song, Jung-Yun Kim, Sang-Yoon Park, Myong Cheol Lim  
Goyang, Seoul, Daegu, Suwon (Republic of Korea)*

**P134 - A prospective study for clinical and pharmacological properties of mitomycin-C induced severe neutropenia after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy**

*Hye Jung Cho, Kyung Sun Moon, Sung-Hoon Ahn, Seung Hyuk Baik, Eun Jung Park  
Seoul, Kangwondo (South Korea)*

**P136 - Screening- and psychological treatment for patients with psychological and biobehavioral late effects following surgery for peritoneal metastases from colorectal cancer – a feasibility study**

*R. Balachandran, H. Vind Thaysen, P. Christensen, L. Maria Wu, S. Møgelberg Knutzen, J. Tingdal Taube Danielsen, L. Hjerrild Iversen  
Aarhus, Denmark.*

**P137 - Multivariate Analysis of Prognostic Factors in the Disease Course of Peritoneal Carcinomatosis**

*Xu Da-zhao, Lin Yu-lin, Ma Ru, Zhao Xin, Yang Rui, Li Yan  
Beijing (China)*

**P138 - Hyperthermic intraperitoneal chemotherapy with gemcitabine in patients with resected pancreatic adenocarcinoma: Clinical trial EudraCT 2016-004298-41**

*D. Padilla-Valverde, S. Sánchez-García, C. Manzanares-Campillo, M. Rodríguez, L. López, J. Martín-Fernández  
(Spain)*

**P139 - Phase I study evaluating the use of personalized chemotherapeutic dosage during HIPEC calculated by the remaining peritoneal surface area after cytoreductive surgery in patients with colorectal peritoneal metastases (pmCRC)**  
*T. Jäger, P. Schredl, D. Neureiter, J. Presl, K. Emmanuel, S. Regenbogen, J.P. Ramspott Muenster Rhein (Germany); Salzburg (Austria)*

**P140 - EFFIPEC: Phase I Study of Hyperthermic Intraperitoneal Chemotherapy in Patients with Colorectal Cancer Peritoneal Metastasis**  
*E. Bexé Lindskog, L. Ghanipour, G. Jansson Palmer, D. Asplund, T. Swartling, J. Nilsson, C. Nordenvall, J. E. Frödin, W. Graf, H. Birgisson, V. Verwaal, I. Syk, P. H. Cashin Peter  
 Gothenburg, Uppsala, Stockholm, Malmö (Sweden)*

**P141- Clinical trial: OLIPPEC 'Cytoreduction, HIPEC and local treatment for patients with colorectal peritoneal and limited liver/lung metastases; a phase II trial'**  
*J.B. Tuynman, T.E. Buffart  
 Amsterdam (Netherlands)*

**P142 - Gastrointestinal stimulation as a treatment of postoperative ileus following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (STIMULATE) - An ongoing prospective blinded randomized controlled clinical trial.**  
*M. M. Sørensen, L.H. Iversen, J.A. Funder  
 Aarhus (Denmark)*

**P143 - Bowel Anastomosis After or Before HIPEC: A Comparative Study in Patients Undergoing CRS+HIPEC for Peritoneal Surface Malignancy- ISPSM COLLABORATIVE STUDY**  
*S.P. Somashekhar, K.R. Ashwin, Y. Ramya, A. Vijay, A. Marian Fernandes, B. Teja Udayee, K. Agrawal, S. Sonkusare, C. Rohit Kumar  
 Bangalore (India)*

**P144 - Hemodynamic and respiratory implications of high intra-abdominal pressure during HIPEC**  
*A. C. V. Reis, S. Kusamura, N. Azmi, L. Fumagalli, F. Piccioni, F. Valenza, D. Baratti, M. Guaglio, A. Cavalleri, G. Garrone, F. Barretta, M. Deraco  
 Milano (Italy), San Paolo (Brazil)*

**P145 - Postoperative ctDNA methylation profile of different recurrence sites of colorectal cancer patients**  
*Lingyu Han, Shaobo Mo, Li Ye, Dongyang Wang, Shuang Zhou, Hui Wang, Weixing Dai, Yichao Wang, Wenqin Luo, Renjie Wang, Ye Xu, Sanjun Cai, Rui Liu, Zheng Wang, Guoxiang Cai  
 Shanghai (China)*

**P146 - The prognostic value of distinct histological growth patterns of colorectal peritoneal metastases**  
*G. Liberale, L. Kamdem, A. El Asmar, I. Zana, C. Khaled, F. Sclafani, V. Donckier, P. Vermeulen, P. Demetter  
 Antwerp, Brussels (Belgium)*

**P147 - Prospective study on the incidence of inferior epigastric lymph node involvement in patients treated for colorectal peritoneal carcinomatosis**  
*G. Liberale, A. El Asmar, C. Khaled, M. Gomez, A. Hendlisz, V. Donckier  
 Brussels (Belgium)*

**P148 - Prospective study on the incidence of inferior epigastric lymph node involvement in patients treated for ovarian peritoneal carcinomatosis**

G. Liberale, A. El Asmar, C. Khaled, M. Gomez, L. Polastro, V. Donckier, I. Veys  
Brussels (Belgium)

**P149 - Progress of the GECOP-MMC trial**

F. Pereira, A. Serrano, I. Manzanedo, E. Pérez-Viejo, E. Asensio, L. González-Bayón, M. E. Barrios, E. Turienzo, J. Galindo, A. Calero, A. Arjona-Sánchez, B. Martínez-Torres  
Madrid, Cordoba, Castellon, Oviedo, Valencia, Valladolid (Spain)

**P151 - Intraperitoneal oxaliplatin associated with systemic chemotherapy beyond the second line for unresectable peritoneal metastases of colorectal origin:**

**NIPOX dose-escalating phase I trial**

O. Sgarbura, D. Tosi, C. Cusumano, S. Poujol, M. Larroque, S. Gourgou, G. De Meeus, A. Bouillin, M.-H. Pissas, M. Al Hosni, T. Mazard, E. Samalin, F. Quénet  
Montpellier, Strasbourg (France); Muscat (Oman)

**P152 - A Prospective Randomized Crossover Trial Demonstrates 5-FU-based Chemotherapy is Ineffective for Patients with Low-Grade Mucinous Appendiceal Adenocarcinoma**

A. Yousef, M. Zeineddine, F. Zeineddine, N. Hornstein, K. Beatty, Wai Chin Foo, M. Taggart, M. White, A. Uppal, B. Helmink, P. Mansfield, C. Scally, K. Raghav, M. Overman, K. Fournier, J. Paul Shen  
Houston (USA)

**P153 - Peritoneal Recurrence a Potential Surrogate Endpoint for Overall Survival in Cytoreductive Surgery/ Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) Clinical Trials**

C. Zhang, D. D. Hegholz, P. Sharma, M. M. Neal, V. Shostrom, J. M. Foster  
Nebraska (USA)

**DIAGNOSIS AND STAGING ON PERITONEAL SURFACE MALIGNANCIES**

Chairperson: *Franco Iafrate (Roma)*

**P154 - Modified peritoneal cancer index based on ultrasonography and CT in predicting completeness of cytoreduction and survival of pseudomyxoma peritonei**

Lei Liang, Xuedi Han, Nan Zhou, Ruiqing Ma, Hong-Bin Xu  
Beijing (China)

**P155 - Shearing through mucin – the utility of shear wave elastography in PMP**

Y. Gao, M. Breakeit, S. J. Valle, D. L. Morris  
Sydney (Australia)

**P156 - Staging peritoneal metastases in colorectal cancer: the correlation between MRI, surgical and histopathological peritoneal cancer index**

C.J.V. Rijsemus, N.F.M. Kok, A.G.J. Aalbers, R.J.A. Fijneman, P. Snaebjornsson, M. Lopez, D.M.J. Lambregts, R.G.H. Beets-Tan, M.J. Lahaye  
Amsterdam (Netherlands)

**P157 - Radiological mimics of peritoneal disease – an imaging case based review**

O. Duxbury, J. El-Sheikha, D. Patel, A. Thrower, N. Shah  
Basingstoke (UK)

**P158 - Should Laparoscopic Staging Enter Routine Practice in Colorectal Peritoneal Carcinomatosis?**

P.Özcan, M.Kalın, Ö. Düzgün, Ö. Faruk Özkan  
Istanbul (Turkey)

**P159 - Impact of previous abdominal surgery and timing of peritoneal metastases on accuracy of imaging in predicting the surgical PCI- A report from the PRECINCT study**

A. Bhatt, P. Rousset, D. Baratti, D. Biacchi, N. Benzerdjeb, A. Buseck, I. Bonnefoy, S. Barat, M. Deraco, D. Morris, A. Souadka, M. Alyami, V. Gushchin, N. Shah, G. Adeleke, S. Stanford, V. Mark Samuel, K. Cummins Perry, B. El Khannousi, S. Khouchoua, N. El Bahaoui, U. Sarpel, D. Labow, N. Khajouejinejad, S. Troob, F. Mohammad, B. Moran, E. Levine, V. Kepenekian, L. Villeneuve, P. Sammartino, A. Sardi, O. Glehen  
Ahmedabad (India); Sydney (Australia); Roma, Milano (Italy); New York, Baltimore, Winston-Salem (USA); Lyon (France); Najran (Saudi Arabia); Basingstoke (UK); Rabat (Morocco)

**P160 - Create a network is the key to achieve results: SICO (Italian Society of Surgical Oncology) peritoneal surface malignancies (PSM) oncoteam experience.**

M. Vaira, A. Sommariva, An. Macri, SICO PSM ONCOTEAM and M. Deraco  
Torino, Milano, (Italy)

**P161 - Second-look diagnostic laparoscopy in patient selection for conversion to complete cytoreductive surgery in colorectal and appendiceal peritoneal metastases**

Y. Hayashi, K. Aso, S. Okamoto, N. Kokudo, H. Yano  
Southampton (UK), Tokyo (Japan)

**P162 - The surgical PCI is an objective score based on a subjective evaluation of disease in the peritoneal cavity- a report from the PRECINCT study**

A. Bhatt, S. Barat, F. Mohammad, D. Baratti, D. Biacchi, N. Benzerdjeb, A. Buseck, I. Bonnefoy, M. Deraco, D. Morris, A. Souadka, M. Alyami, V. Gushchin, N. Shah, G. Adeleke, S. Stanford, V. Mark Samuel, K. Cummins Perry, B. El Khannousi, S. Khouchoua, N. El Bahaoui, U. Sarpel, D. Labow, N. Khajouejinejad, S. Troob, V. Kepenekian, B. Moran, E. Levine, P. Rousset, L. Villeneuve, P. Sammartino, A. Sardi, O. Glehen  
Ahmedabad (India); Sydney (Australia); Roma, Milano (Italy); New York, Baltimore, Winston-Salem (USA); Lyon (France); Najran (Saudi Arabia); Basingstoke (UK); Rabat (Morocco)

**P163 - Correlation between intra-operative morphology of peritoneal metastases and the presence of disease on pathology in patients undergoing cytoreductive surgery- A report from the PRECINCT study**

A. Bhatt, V. Gushchin, D. Baratti, D. Biacchi, N. Benzerdjeb, A. Buseck, I. Bonnefoy, S. Barat, M. Deraco, D. Morris, A. Souadka, M. Alyami, F. Mohammad, N. Shah, G. Adeleke, S. Stanford, V. M. Samuel, K. Cummins Perry, B. El Khannousi, S. Khouchoua, N. El Bahaoui, U. Sarpel, D. Labow, N. Khajouejinejad, S. Troob, V. Kepenekian, B. Moran, E. Levine, P. Rousset, L. Villeneuve, P. Sammartino, A. Sardi, O. Glehen  
Ahmedabad (India); Baltimore, New York, Winston-Salem (USA); Milan, Rome (Italy); Lyon (France); Sydney (Australia) Rabat (Morocco); Basingstoke (UK)

**P164 - Deep learning based on CT images for the prediction of cytoreductive surgery in peritoneal metastasis of colorectal cancer**

Zixu Yuan, Can Chen, Zaisheng Ye, Qingfeng Lin, Hui Wang, Kangshun Li, Renjie Wang, Shuai Han  
Guangzhou, Fuzhou, Shanghai (China)

**P165 - Prognostic significance of lymphatic spread without extrapelvic peritoneal seeding in advanced ovarian cancer: a retrospective cohort study**

*Min Kyung Kim, Nam Kyeong Kim, Dong Hoon Suh, Kidong Kim, Jae Hong, Yong Beom Kim Seongnam (Korea)*

**P166 - Validation of surgical Peritoneal Cancer Index (sPCI) as a prognostic marker in ovarian cancer patients undergoing Interval Cytoreductive Surgery & Hyperthermic Intraperitoneal Chemotherapy (ICS-HIPEC): An Indian Collaborative Study**

*B. Bansal, M.D. Ray, S.V.S. Deo, A. Mishra, D. Goel  
New Delhi (India)*

**P167 - The divergence of the peritoneal carcinoma index: diagnostic imaging vs. surgical exploration**

*K. Strohmeier, G. Suppan, A. Ruppert-Kohlmaier, R. Schrittwieser  
Leoben (Austria)*

**P168 - Pseudomyxoma peritonei originating in the ovary: 19 cases with clinicopathological and molecular characterization and systematic review of the literature with pooled analysis**

*L. van der Snee, B. L.M. Ykema, P. Lof, A. G.J. Aalbers, H. van Boven, N. F.M. Kok, C. A.R. Lok, K. K. van de Vijver, P. Snæbjörnsson  
Amsterdam (Netherlands); Ghent (Belgium)*

**P169 - Comparison between MRI and conventional CT scans in the prediction of Peritoneal Cancer Index.**

*M. Polici, M. Zerunian, B. Masci, A. Del Gaudio, D. De Santis, D. Caruso, P. Sammartino, A. Laghi  
Roma (Italy)*

**P170 - Implementation of a Program for the Detection and Treatment of Gastric Cancer Peritoneal Metastasis: Improving Patient Selection and Therapeutic Approach in a low-resources Health Institution**

*G. Flores Ayala, N. Luna Romero, C. Barrera Zamora, J. Carlos Vazquez Limon, V. Coss y Leon Jalisco (Mexico)*

**P171 - Impact of preoperative peritoneal MRI on surgical decisions in patients scheduled**

**for iterative cytoreductive surgery**  
*A. Singh, G. Goswami, A. Patel, A. Bhatt  
Ahmedabad (India)*

**PIPAC**

**Chairperson:** *Marco Vaira (Torino)*

---

**P172 - Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in India: the past, present and future**

*V. Gaikwad, J. Bhat  
Haryana (India)*

**P173 - First-line palliative systemic therapy alternated with oxaliplatin-based Pressurized Intraperitoneal Aerosol Chemotherapy for unresectable colorectal peritoneal metastases: a single-arm phase II trial (CRC-PIPAC-II).**

*P. Rauwerdink, V. C.J. van de Vlasakker, E.C.E. Wassenaar, K.P. Rovers, M. Los, K. H. Herbschleb, G. M. Creemers, A.M.J. Thijs, M.G. Raicu, C. J.R. Huysentruyt, E. J.R.J. van der Hoeven, J. Nederend, R. M.Y.M. Peeters, M.J. Deenen, S. G. Elias, R. J.A. Fijneman, A. Constantinides, O. Kranenburg, P.J.W.A. Burger, S. W. Nienhuijs, R. J. Wiezer, R. J. Lurvink, I.H.J.T. de Hingh, D. Boerma*  
 Eindhoven, Noord-Brabant, Eindhoven, Nieuwegein, Noord-Holland, Utrecht, Limburg (Netherlands)

**P174 - PIPAC – first experience with the new intraperitoneal chemotherapy**

*D. Hoskovec, M. Vocka, Z. Krska, P. Dytrych*  
 Prague (Czech Republic)

**P175 - Feasibility and Safety of Taxane-PIPAC in Patients with Peritoneal Malignancies-a Retrospective Bi-institutional Study**

*M. Sanket, K. Praveen, P. Ankita, G. Gaurav, S. Sakina, S.Vivek, T. Esha, B. Aditi*  
 Maharashtra,Gujarat, (India)

**P176 - Early Experience with PIPAC in a Private Australian Hospital**

*A.C. Lynch, A. Zimet*  
 Melbourne (Australia)

**P177 - Safety, quality of life and cost-utility in patients treated with pressurized intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis**

*M. Cai, J. Wong, D.Juan, P. Lin Koh, C. Jin Seo, J. Ong, C. Chia*  
 Singapore (Republic of Singapore)

**P178 - Evaluation of Feasibility and Patient Selection for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) following Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Retrospective Study.**

*N. Rüedi, S. Chin Jin, J. Wong Si Min, J. Chin Ann Ong, C. Chia Shulyun*  
 Singapore (Republic of Singapore)

**P179 - Feasibility & clinical outcomes with escalated doses of cisplatin (15mg/m<sup>2</sup>) and doxorubicin (3mg/m<sup>2</sup>) in PIPAC for inoperable peritoneal carcinomatosis of epithelial ovarian cancer- ISPSM Collaborative Study**

*C. Rohit Kumar, S.P. Somashekhar, K.R. Ashwin, D. Patil, G. Girish, V. Ahuja*  
 Bangalore (India)

**P181 - Impact of Body Mass Index on postoperative pain and opioid administration after pressurized intraperitoneal aerosol chemotherapy (PIPAC)**

*F. Tidadini, B. Trilling, J.-L. Quesada, J. Abba, A.Foote, J.-L. Faucheron, C. Arvieux*  
 Lyon, Grenoble (France)

**P183 - Application of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of gastric cancer peritoneal carcinomatosis: current relevance of new loco-regional tools in the era of metastatic patient care in a tertiary referral center for gastric cancer**

*A. Cossu, R. Calef, A. Carresi, S. Battaglia, F. Puccetti, L. Barbieri, L. Cinelli, E. Treppiedi, U. Elmore, R. Riccardo*  
 Milano (Italy)



**P184 - Safety Evaluation Of A Personalized Treatment For Liposarcoma Peritoneal Metastasis, Using An "In Vitro" Sensitivity Test To Guide Pressurized Intraperitoneal Aerosolized Chemotherapy – PIPAC.**

C. A. Quadros, P. Borriane, V. Campos Duarte, D. Pereira Bezerra, A. K. Araújo Mascarenhas O. Bastos, M. Botelho Pereira Soares, L. De Souza Santos, V. Rodrigues Silva  
Bahia (Brazil)

**P185 - Pressurized Intraperitoneal Aerosolized chemotherapy (PIPAC) in recurrent ovarian and gastric cancer patients with peritoneal metastases: Safety and efficacy of a first-in-US phase I study**

T. H. Dellinger, D. Desperalta, Y. Woo, D. Stewart, E. Wang, N. Ruel, P. H. Frankel, S. Cole, I. B. Paz, Y. Fong, S. Chang, M. Eng, R. Tinsley, J. Mortimer, J. Villella, M. Cristea, A. Merchea, R. L. Whelan, M. Raouf  
New York (USA); Duarte (CA)

**P186 - Long Term Survival of a Patient with Pancreatic Carcinomatosis Treated with Systemic Chemotherapy plus PIPAC**

M. Uribe, C. Garcia, L. Cereceda, B. Nervi, M. Musleh  
Santiago (Chile)

**P187 - Pressurized intraperitoneal aerosol chemotherapy versus catheter-based intraperitoneal chemotherapy for patients with extensive colorectal peritoneal metastases – comparing results of two early phase trials**

T. B.M. van den Heuvel, V.C.J. van de Vlasakker, P. Rauwerdink, R. A.G. van Eerden, N. L. de Boer, J. P. van Kooten, R.J. Lurvink, E.V.E. Madsen, A. R.M. Brandt-Kerkhof, E. van Meerten, S. W. Nienhuijs, K. P.B. Rovers, C. Bakkers, C. Verhoef, R.H.J. Mathijssen, D. Boerma, I. H.J.T. de Hingh, J. W.A. Burger  
Eindhoven, Rotterdam, Maastricht, Nieuwegein (Netherlands)

**P189 - Initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the management of unresectable peritoneal metastasis in a newly established center**

H. Alhabes, M. Alzamanan, S. Almowallad, M. Alyami  
Najran (Saudi Arabia)

**P190 - Pressurised Intra Thoracic Aerosolised Chemotherapy (PITAC) in malignant pleural effusion of Gastrointestinal origin - A tale of three cases**

N. Katdare, N. Konar, D. Pandya, S. Trivedi  
Maharashtra, (India)

**P191 - Assessing reasons for stopping pressurized intraperitoneal aerosol chemotherapy (PIPAC) treatment in a large patient cohort**

V. Kepenekian, I. Bonnefoy, N. Barkin, O. Glehen  
Pierre-Bénite (France)

**P192 - Safety and feasibility of PIPAC for advanced ovarian cancer: a single center experience**

B. Valenzuela-Mendez, A. Bouillin, G. Guíñez-Robertson, D. Zambrano-Perez, F. Quénet, O. Sgarbura  
Montpellier (France)

## NURSES MANAGEMENT OF PERITONEAL SURFACE MALIGNANCIES

**Chairperson:** *Antonio Sommariva (Padova)*

---

**P193 - Sharing practical knowledge in the management of complex mucinous fistulating Pseudomyxoma Peritonei.**

*E. Maltby, K. Sobanski, P. Green  
Basingstoke (UK)*

**P194 - Brain drain and ward strain challenges on a major peritoneal malignancy unit during the covid pandemic: 12 month snapshot of nursing workforce and patient complications**

*H. Kennedy, M. Carroll, R. Wijayawardana, D. L. Morris  
Sydney (Australia)*

**P195 - Supporting peritoneal tumour patients during the COVID-19 Pandemic**

*R. Halstead, R. Connolly  
Manchester (UK)*

**P196- Exploring the Advanced Nurse Practitioner's role within the Peritoneal Malignancy unit.**

*G. Robbins  
Hampshire (UK)*

## MANAGEMENT OF PERITONEAL MESOTHELIOMA

**Chairperson:** *Yan Li (Beijing)*

---

**P197 - Management of the Uterus and Ovaries during Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy**

*N. M. Winicki, S. N. Radomski, I. S. Florissi, S. Wethington, I. de Hingh, L. Villeneuve, O. Glehen, J. Esquivel, A. Bhatt, F. M. Johnston, J. B. Greer  
Baltimore (USA); Riverside (CA); Eindhoven (Netherlands); Ahmedabad (India)*

**P198 - Establishment of A Bayesian Network Model to Predict the Survival of Malignant Peritoneal Mesothelioma Patients after Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy**

*Yan-Dong Su, Xin Zhao, Ru Ma, Yu-Bin Fu, Zhi-Ran Yang, He-Liang Wu, Yang Yu, Rui Yang, Xin-li Liang, Xue-Mei Du, Yue Chen, Yan Li  
Beijing (China)*

**P199 - Experiences of care and variability in patient pathways in peritoneal mesothelioma - qualitative findings from a UK study**

*S. Westbrook, S. Ejegi-Memeh, V. Sherborne, C. Warnock, S. Stanford, L. Squibb, C. Twist, C. Gardiner  
Sheffield, Manchester, Southampton, Basingstoke (UK)*

**P200 - Virtual Support Groups for Peritoneal Mesothelioma Patients**

*S. Westbrook  
Basingstoke (UK)*

**P201 - Prognostic Factors for Survival in Patients with Diffuse Malignant Peritoneal Mesothelioma - A Single Institution Experience for 20 Years**

*Suk-Joon Chang, J. Lee, J. Kim, Joo-Hyuk Son, MD, Tae-Wook Kong  
Suwon (Republic of Korea)*

**P202 - Diffuse malignant peritoneal mesothelioma - survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC)**

*E. Wagler  
Saxony (Germany)*

**P203 - Clinical Characteristics Analysis of Malignant Peritoneal Mesothelioma with Paraneoplastic Syndrome**

*Xin-Li Liang, Yan-Dong Su, R. Ma, R. Yang, X. Zhao, He-Liang Wu, Xin-Bao Li, Yu-Bin Fu,  
Yu-Lin Lin, Y. Li  
Beijing (China)*

## TREATMENT OF PERITONEAL METASTASES OF OVARIAN CANCER

Chairperson: *S.P. Somashekhar (Bangalore) - N. Bakrin (Lyon)*

---

**P204 - Evaluation of delay in time for adjuvant chemotherapy after HIPEC and its impact on oncological outcome in advanced epithelial ovarian cancer**

*D. Patil, S. P. Somashekhar, V. Ahuja, K. R. Ashwin, R. Yethadka, G. Girish, A. M. Fernandes, Dr Shipra, R. Kumar  
Karnataka (India)*

**P205 - Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer**

*Suk-Joon Chang, J. Lee, Jeeyeon Kim, Joo-Hyuk Son, Tae-Wook Kong  
Suwon (Republic of Korea)*

**P206 - Evaluation of delay in time to adjuvant chemotherapy after HIPEC and its impact on oncological outcome in advanced epithelial ovarian cancer: ISPSM Collaborative study**

*S. P. Somashekhar, Y. Ramya, K. R. Ashwin, V. Ahuja, A. Kumar Namachivayam, A. M. Fernandes, K. Agrawal, B. T. Udayee, S. Sonkusare, R. K. C.  
Bangalore (India)*

**P207 - Prognostic impact of erythropoietin-stimulating agents during front-line chemotherapy in patients with primary ovarian, fallopian, or peritoneal cancer**

*Seung-Hyuk Shim, Eunbi Jang  
Seoul (Republic of Korea)*

**P208 - Laparoscopic HIPEC and bidirectional chemotherapy in the treatment of Advanced Epithelial Ovarian Carcinoma**

*B. Canbay Torun, E. Sobutay, O. E. Akbulut, S. Koc, C. Sezgin, Y. Yonemura, E. Canbay  
Istanbul (Turkey); Kishiwada-Osaka (Japan)*

**P209 - HIPEC in Ovarian cancer. Experience in Kazakh Institute of Oncology and Radiology.**

*A.R. Satanova, D.R. Kaidarova, E.K. Kukubassov, O.O. Bertleuov, D.B. Kaldybekov  
Almaty (Kazakhstan)*

**P210 - Rectal resections without diversion stoma for cytoreductions in Ca ovary - An experience from a high volume team (An Indian collaborative study)**

*N. Garach, V. Sukumar, E. Trivedi, J. Gori, J. Rajpurohit, A. Shah, P. Kammar, N. Choradiya, J. Pandey, S. Mehta  
Maharashtra (India)*

**P211 - Combine of Hyperthermic Intrathoracic and Intraperitoneal Chemotherapy After Limited Liver Resection in Ovarian Cancer Stage IVB**

*C. Sirisai, P. Ratanasrithong, W. Kolaka, U. Kompaibulkij  
Bangkok (Thailand)*

**P212 - Descriptive analysis of patients undergoing cytoreductive surgery for first peritoneal recurrence from Adult Granulosa Cell tumors – Focus on disease distribution and the role of HIPEC**

*S. Sinukumar, M. Ray, D. Damodaran, N. Katdare, S. Vikram, A. Bhatt  
Maharashtra (India); New Delhi (India); Kerala (India); Maharashtra (India); Gujarat (India)*

**P213 - Perioperative and early survival outcomes in 219 patients from the single-arm, prospective TORPEDO study: Total parietal peritonectomy during interval cytoreductive surgery for advanced ovarian cancer**

A. Bhatt MS, S. Sinukumar, D. Damodaran, A. Patel, S. Shaikh, A. Singh, P. Kammar, S. Mehta

Ahmedabad (India); Pune (India); Calicut (India); Mumbai (India)

**P214 - Liver metastases from epithelial ovarian cancer: benefit of liver resection on cytoreduction.**

S. Brozzetti, C. D'Alterio, G. Torzilli, J. Galvanin, F. Romano, G. M. Ettore, S. Ferretti, E. Rosso, A. Fassari, M. Rossi, Q. Lai, E. F. Kauffman, U. Boggi

Rome (Italy); Milan (Italy); Monza (Italy); Luxembourg (Luxembourg); Pisa (Italy)

**P215 - Expression of Cancer Testis Antigen (CTA) - CT45 in advanced epithelial ovarian cancer (EOC) patients undergoing CRS and HIPEC and its correlation with platinum-sensitivity**

N. Premanand, M. D. Ray, S. V. S. Deo, A. Sharma, B. Prasad Jit

New Delhi (India)

**P216 - Predictors of outcome in relapsed epithelial ovarian cancers and model development for secondary cytoreduction selection criteria**

M. D. Ray, N. Premanand, D. Goel

New Delhi (India)

**P217 - Supra-mesocolic lymph node metastases secondary to peritoneal metastases in patients with epithelial ovarian cancer undergoing cytoreductive surgery- results from phase 1 of the PRECINCT study**

A. Bhatt, P. Sammartino, D. Baratti, D. Biacchi, N. Benzerdjeb, A. Buseck, I. Bonnefoy, S. Barat, M. Deraco, D. Morris, A. Soudka, M. Alyami, V. Gushchin, N. Shah, G. Adeleke, S. Stanford, M. S. Vasanth, K. Cummins Perry, B. El Khannousi, S. Khouchoua, N. El Bahaoui, U. Sarpel, D. Labow, N. Khajouejinejad, S. Troob, F. Mohammad, B. Moran, E. Levine, V. Kepenekian, P. Rousset, L. Villeneuve, A. Sardi, O. Glehen

Ahmedabad (India); Rome (Italy); Milan (Italy); New York (USA); Sydney (Australia);

Najran (Saudi Arabia); Baltimore (USA); Basingstoke (UK); Winston-Salem (USA);

Rabat (Morocco); Lyon (France)

**P218 - Pseudo cytoreductive surgery is a hard reality in advanced ovarian cancer management- Experience from pattern of referral to our tertiary oncology center India**

M.D. Ray, N. Premanand, C. Ray

New Delhi (India)

**P219 - Incidence of histologically confirmed upper abdominal disease in patients undergoing systematic total parietal peritonectomy during interval cytoreduction for ovarian cancer-analysis from the TORPEDO study**

A. Bhatt, D. Damodaran, S. Sinukumar, A. Patel, S. Shaikh, A. Singh, P. Kammar, S. Mehta

Ahmedabad, Calicut, Pune, Mumbai (India)

**P221- Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum resistant ovarian cancer – Interim analysis of randomized control trial**

C. Rohit Kumar, S.P. Somashekhar, K.R. Ashwin, K. DPriya, A. Marian Fernandes, S. Rakshit, D. Patil, G. Girish, C. N. Patil, S. Vivek, V. S. Joshi, A. Kumar Namachivayam, V. Ahuja

Bangalore, Chennai (India)

**P222 - Prognostic Significance of CA-125 ELIMINATION Rate Constant K and Its Correlation with Chemotherapy Response Score in Ovarian Cancer Patients Treated with Hyperthermic Intraperitoneal Chemotherapy**

*L. Felipe Falla-Zuniga, K. Studeman, F. Lopez-Ramirez, M. Caitlin King, V. Gushchin, C. Nieroda, T. Diaz-Montes, A. Sardi  
Baltimore (USA)*

**P223 - Clinicopathologic factors associated with long-term survival in advanced epithelial ovarian cancer with peritoneal metastasis**

*Eun Bi Changm, Seung-Hyuk Shim  
Seoul (Republic of Korea)*

**P224 - Early Postoperative Intraperitoneal Chemotherapy Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Ovarian Cancer with Peritoneal Metastasis: Outcome Analysis in A Pilot Study**

*P. Dranichnikov, H. Mahteme, P. Cashin  
Västerås (Sweden); Uppsala (Sweden)*

**P225 - Influence of chemotherapy before Secondary cytoreduction on Survival in Recurrent high-grade serous Ovarian cancer**

*V. Sukumar, E. Trivedi, J. Rajpurohit, P. Kammar, S. Mehta  
Maharashtra (India)*

**P226 - Cytoreductive surgery for ovarian peritoneal metastases: role of a dedicated multidisciplinary team in therapeutic pathways**

*M. Tonello, C. Cenzi, E. Pizzolato, E. Porcu, C. Ruzzante, G. Ramondo, F. Bergamo, F. Daniel, S. Frezzini, G. Tasca, A. Baldoni, M. Martini, A. R. Cervino, A. Scapinello, S. Lonardi, A. Sommariva, P. Pilati  
Mirano, Padova (Italy)*

**P228 - Excellent disease free and overall survival in mucinous and borderline ovarian neoplasms in women treated by cytoreductive surgery (CRS) and HIPEC.**

*S. Addley, V. Mark Samuel, K. Chandrakumaran, F. Mohamed, T. Cecil, B. Moran  
Basingstoke (UK)*

**P229 - Interval debulking surgery (IDS) and Heated intraperitoneal chemotherapy (HIPEC) for advanced-stage ovarian cancer: report of a Single-Center Experience in the UK**

*C. Liakou, A. Pandrklakis, M.C. La Russa, H. Turnbull, J. Nieto, T. Duncan, A. Stearns, N. Burbos  
Norwich (UK)*

**P231 - Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Literature Review and Presentation of Surgical Experience**

*FS. García, F. A. De Sà Riberio  
Rio de Janeiro (Brazil)*

**P232 - HIPEC in ovarian cancer: Who lives the longest?**

*J. M. Medina-Castro, A. Berenice González-Valdés, F. Rivera-Buendía, D. Rivera-Buendía  
Toluca (Mexico)*

**P233 - Complete Cytoreduction and HIPEC for Peritoneal Carcinomatosis in Ovarian Cancer in Hospital Universitario Nuestra Señora de Candelaria: Morbidity, Mortality, and Survival Analysis.**

*J. Abellán Fernández, M. Rojas Estevez, V. Concepción Martín, C. Díaz López, R. Hareh Gianchandani Moorjani, R. Orti Rodríguez, J. Manuel Sánchez González, A. Ángel Quesada López-Fe, J. Antonio Pérez Álvarez, J. Miguel del Pino Monzón, E. Moneva Arce, M. Ángel Barrera Gómez  
Santa Cruz of Tenerife (Spain)*

## BASIC RESEARCH

**Chairperson:** *Manuela Gariboldi (Milano) - Marc Pocard (Paris)*

---

**P234 - Orthotopic PDX & Organoid Models of Appendiceal Adenocarcinoma for the Discovery of Novel Active Drugs in this Orphan Disease**

*I. Ito, A. Yousef, J. Dansby, S. Chowdhury, V. Haridas, M. White, N. Fowlkes, B. Helmink, K. Flatmark, K. Fournier, J. P. Shen  
Houston (USA)*

**P235 - Effectiveness of different oncolytic vaccinia virus strains for the in vitro and in vivo treatment of peritoneal mesothelioma**

*C. Yurttas, J. Beil, S. Berchtold, I. Smirnow, L. D. Kloker, B. Sipos, A. Königsrainer, U. M. Lauer, K. Thiel  
Tübingen, Stuttgart (Germany)*

**P236 - Immunotherapy combined with heated intraperitoneal chemotherapy improves outcome in experimental model of peritoneal metastases from colonic origin**

*R. Geva, G. Alon, N. Nevo, A. Aizic, G. Lahat, E. Nizri  
Tel Aviv (Israel)*

**P238 - The oncologic effects according to the carrier fluids on the oxaliplatin-based hyperthermic intraperitoneal chemotherapy using the colon cancer syngeneic mouse model with peritoneal metastasis**

*E. Jung Park, H. J. Park, C. K. Lee, I. Kyung Hong, S. Hyuk Baik  
Seoul, Yongin-si (Korea)*

**P239 - New drug development of sustained-release oxaliplatin-loaded multi-vesicular liposomal depot for intraperitoneal chemotherapy to treat colorectal cancer with peritoneal carcinomatosis**

*E. Jung Park, S. Md Abuzar, J. Lee, Yeji Seo, S. J. Hwang, S. Hyuk Baik  
Seoul, Incheon (South Korea)*

**P240 - A novel porcine model for dynamic in situ assessment of cisplatin concentrations in carcinomatosis relevant tissues during and after a HIPEC-procedure**

*C. Harlev, E. Krogsgaard Petersen, B. Martin Bibby, A. René Jørgensen, M. Bue, P. Hanberg, M. Stilling, A. Vibeke Schmedes, L. Kjeld Petersen  
Aarhus, Vejle (Denmark)*

**P242 - Features of mucin and its implication in pseudomyxoma peritonei**

*P. Villarejo-Campos, S. Qian, V. Domínguez-Prieto, M. García-Arranz, S. Jiménez Galanes, J. Felipe Vélez-Pinto, I. Guijo Castellano, M. Jiménez-Fuertes, H. Guadalajara Labajo, D. García-Olmo  
Madrid (Spain)*

**P243 - Infiltrating innate lymphoid cells in colorectal cancer with peritoneal metastases**

*M. Ljunggren, A. Marchalot, I. Meninger, W. Weigel, C. Stamper, C. Tibbitt, R. Vinay Pandey, M. Ahlberg, U. Lindfors, G. Jansson-Palmer, Ca. Nordenvall, J. Mjöberg  
Stockholm (Sweden)*

**P244 - Using shear wave elastography to assess the effect of BROMAC on mucin**

*Y. Gao, H. K. Bains, M. Breakeit, S. J. Valle, D. L. Morris  
Sydney, Mucpharm Pty (Australia)*

**P245 - Metastatic colorectal carcinoma-associated fibroblasts display an IGFBP2-dependent immunosuppressive effect on the tumour microenvironment**

C. Ramos, N. Walterskirchen, C. Müller, M. Sachet, L. Unger, V. Gerakopoulos, M. Bergmann, H. Dolznig, T. Bachleitner-Hofmann, R. Oehler  
Vienna (Austria)

**P246 - Abdominal tissue concentrations and penetration of carboplatin in a HIPEC procedure - assessment in a novel porcine model**

E. Krosgaard Petersen, M. Bue, C. Harlev, A. René Jørgensen, A. Vibeke Schmedes, P. Hanberg, L. Kjeld Petersen, M. Stilling  
Aarhus, Vejle (Denmark)

**P247 - Breaking the mucin barrier: Discovering and testing new therapeutic targets in Pseudomyxoma peritonei**

A. Romero-Ruiz, M. Granados-Rodríguez, F. I. Bura, F. Valenzuela Molina, B. Rufián-Andújar, A. Martínez-López, L. Rodríguez Ortiz, R. Ortega-Salas, C. Michán, J. Alhama, M.C. Vázquez-Borrego, Á. Arjona-Sánchez  
Cordoba (Spain)

**P248 - Effect of FOLFOXIRI plus Bevacizumab treatment of colorectal peritoneal carcinomatosis on local and systemic immune cells**

C. Müller, A. Beer, H. Birnleitner, M. Rainer, M. Sachet, T. Bachleitner-Hofmann, R. Oehler  
Vienna (Austria)

**P249 - Prognostic impact of iatrogenic rupture in early stage ovarian cancer**

E. Bi Jang, A. Jin Lee, Seung-Hyuk Shim  
Seoul (Korea)

**P251 - Genetic Specificity Study using Next Generation Sequencing(NGS) of Peritoneal Metastatic Colorectal Cancer Compared to Primary Colorectal Cancer**

Sung Chul Lee  
Chungnam (Korea)

**P252 - Eosinophils might be related with the response of peritoneal metastases against intraperitoneal chemotherapy in patients with gastric cancer.**

K. Takahashi, M. Matsumiya, Y. Kaneko, K. Kurashina, S. Saito, H. Miyato, Y. Hosoya, N. Sata, H. Ohzawa, H. Yamaguchi, J. Kitayama  
Shimotsuke (Japan)

**P253 - Umbilical Cord Blood-Derived Natural Killer Cells Suppress Human Malignant Peritoneal Mesothelioma Cell in a Tumor-Cell Density Dependent Manner**

He-Liang Wu, Yi Wang, Ya-Jing Huang, Chun-Ning Lai, Yu-Lin Lin, Xue-Mei Du, Yan-Dong Su, Ru Ma, Zhi-Ran Yang, Rui Yang, Yan Li  
Beijing (China)

**P254 - DOES CRS+ HIPEC ALTER THE IMMUNE TUMOR MICROENVIRONMENT IN ADVANCED EPITHELIAL OVARIAN CANCER? – A STUDY ON TREG (FOXP3), TH17 (ROR $\gamma$ ) CELLS AND INTERLEUKINS**

M.D. Ray, P. N, K. luthra, S. R. Mathur, S.V.S. Deo  
New Delhi (India)

**P255 - Peritoneal Metastasis-derived Extracellular Matrix Proteins Regulate the Tumor Microenvironment Leading to an Impairment of the Immune Cells Antitumor Activity**

E. Daveri, D. Battistessa, F. Farris, C. Paolino, S. Zanutto, F. Pisati, O. Illescas, L. Cattaneo, M. Guaglio, D. Baratti, A. Bachi, L. Rivoltini, M. Deraco, M. Gariboldi  
Milano (Italy)



**P256 - Preliminary ex vivo validation of clinical utility of CyPH-11 to detect peritoneal metastases**

Q. Xuan Tan, J. Wee-Shan Tan, Gillian Ng, Y. Liu, C. Yieh Lin Chong, C. Jin Seo, J. Si Min Wong, C. Shulyin Chia, Ching-Hsuan Tung, B. D Gray, K. Y Pak, Chin-Ann Johnny Singapore (Republic of Singapore); New York, Pennsylvania (USA)

**P257 - Deciphering the interplay of tumor cells, immune cells and fibroblasts of peritoneal metastases of colorectal cancer using a 3D co-cultivation system**

N. Walterskirchen, C. Ramos, C. Müller, H. Dolznig, T. Bachleitner-Hofmann, R. Oehler Vienna (Austria)

**P258 - Development of a novel gene therapy targeted microRNA for peritoneal metastases of gastric cancer**

H. Ohzawa, Y. Kaneko, R. Takahashi, Y. Kimura, H. Miyato, H. Yamaguchi, Y. Hosoya, N. Sata, J. Kitayama Tochigi (Japan)

**P259 - Optimising NGS protocols for patient samples with low tumour cellularity: towards enabling a molecular characterisation of PMP.**

R. T. Nagaraju, B. Chakrabarty, A. Hasan, S. T O'Dwyer, O. Aziz, J. Barriuso Manchester (UK)

**P260 - Peritoneal fibroblasts from metastatic colorectal cancer protect tumor spheroids against chemotherapeutic drugs in vitro**

V. Gerakopoulos, S. Vintila, C. Ramos, V. Nori, M. Sachet, C. Müller, T. Bachleitner-Hofmann, R. Oehler Vienna (Austria)

**P261 - The effect of gastrointestinal electrical stimulation on postoperative ileus in animals undergoing surgery and HIPEC**

C. Harlev, E. K Petersen, M. M Sørensen, L. H. Iversen, J. A. Funder Aarhus (Denmark)

**P262 - A multidisciplinary approach to optimising tissue biobanking for appendix tumours and pseudomyxoma.**

R.T Nagaraju, J. Barriuso, J. Rogan, O. Aziz, S. T O'Dwyer, B. Chakrabarty Manchester (UK)

**P263 - Quantitative proteomics analysis to understand the role of the human appendix: Does its proteome hold the key?**

A. M. Vasilogianni, C. Demonacos, S. T. O'Dwyer, O. Aziz, S. Annie Peters, A. Rostami-Hodjegan, J. Barber Manchester (UK); Rhein (Germany)

**P264 - Circulating tumor DNA for monitoring patients with pseudomyxoma peritonei**

A. Torgunrud, C. Lund-Andersen, I. Katrine Nitschke Pettersen, B. Davidson, V. Dagenborg, K. Flatmark Oslo (Norway)

**P265 - Correlation between biological and mechanical properties of extracellular matrix and peritoneal metastasis in human tissues**

L. Varinelli, M. Chighizola, S. Brich, F. Pisati, M. Guaglio, D. Baratti, M. Deraco, M. Gariboldi, A. Podesta Milano (Italy)

**P266 - Landscape of immune microenvironment in Peritoneal Metastasis of LAMN Revealed by Single-Cell RNA Sequencing**

Lingyu Han, Wenqin Luo, Renjie Wang, Guoxiang Cai  
Shangai (China)

**P267 - Effect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Peripheral FOXP3 Treg and ROR $\gamma$  Th17 Cells in Patients with Ovarian Cancer**

M.D. Ray, B. Bansal, S.V.S.Deo, Premanand, V. Ravi  
New Delhi (India)

**P268 - Peritoneal and Plasma Pharmacokinetics of Nano-Doxorubicin in Peritoneal Metastasis**

N. Nesetoglu, B. Canbay Torun, E. Canbay, D. Özer Ünal  
Istanbul (Turkey)

**P269 - Evaluation of the particle size, distribution and depth of penetration of doxorubicin Nano Aerosolized Chemotherapy (NAC) in an experimental study**

M. Sanket, K. Praveen , B. Aditi , N. Garach, V. Chavan, S. Ahir  
Maharashtra (India)

**P271 - Does the use of Biosynthetic or Biological mesh increases peritoneal metastasis growth in animal model?**

R. Lo Dico, C. Pimpie, R. Kaci, M. Pocard  
Paris (France)

**P273 - The impact role of the imunonutricional care and its effects for citorreductive surgery with HIPEC**

R. Seitenfus, A. C. Fleig, C. Cereser, E. Dipp, A. Santana da Luz, M. Machado Araujo, J. Severo Ribeiro, A. Peres, B. Isidoro, G. Fardin  
Porto Alegre (Brazil)

**P275 - Contribution of Extracellular Vesicles in the Treatment of a Murine Model of Peritoneal Carcinomatosis of Colonic Cancer**

M. Thaury, P. Cynthia, V. Jeanne, J. Branchu-Capdevielle, C. Simon, F. Gazeau, M. Pocard  
Paris (France)

**P276 - Immune Cell infiltrates in Peritoneal Metastases from Colorectal Cancer – Insights for Immunotherapy**

M. Quiding Järbrink, P.Sundström, W. Rodin, S. Hogg, E. Bexe Lindskog  
Gothenburg (Sweden)

**P277 - Study of the therapeutic efficacy in the treatment of colorectal cell models through the use of “step-up” heating during HIPEC sessions and the possibility of using this method in animal models**

B. Bokan, R. F.C.P.A. Helderma, H. M. Rodermond, G. van Bochove, H. Petra Kok, P. J Tanis, J. Tuynman, J. Crezee, A. L. Oei  
Amsterdam (Netherlands)

**P278 - Preventing Regrowth of Peritoneal Metastasis-Derived Organoids Following MMC Treatment Using the ATR Inhibitor Berzosertib**

V. Megesen, M. Kieboom, O. Kranenburg  
Utrecht (Netherlands)

## PERIOPERATIVE CARE

**Chairpersons:** Aviran Nissan (Telaviv) - Massimo Framarini (Forli)

---

**P279 - Home parenteral nutrition in cytoreductive surgery patients in the palliative setting: a case series**

M. Brown, H. Dragicevich, R. Pons, M. Breakeit, N. Ahmadi, F. van Haren, D. L. Morris  
Sydney (Australia)

**P280 - Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: ISPSM Collaboration Study.**

A. Kushal, S. P. Somashekhar, K.R. Ashwin, Y. Ramya, A. Vijay, G. Girish, A. Marion Fernandes, D. Patil, U. Teja Bathala, Shipra, C. Rohit Kumar  
Bangalore (India)

**P281 - Fluid dynamics – the neglected 3rd column of CRS and HIPEC**

H. G. Becker  
Saarbrücken (Germany)

**P282 - Retrospective Cohort: postoperative complications, mortality, length of ICU stay, and total internation of HIPECS patients from 2014-2023 in a southern brazilian Hospital**

A. Peres, J. Severo Ribeiro, A. Santana Da Luz, E. Dipp, R. Seitenfus Ds, A. C. Fleig, M. Machado Araujo, C. Cereser, L. Immich, J. Weizenmann Junior  
Porto Alegre (Brazil)

**P283 - Thromboelastogram Dynamics As a Marker for Postoperative Complications after Cytoreductive Surgery**

N. Goder, L. Zac, N. Nevo, F. Gerstenhaber, O. Goren, B. Cohen, G. Lahat, E. Nizri  
Tel-Aviv (Israel)

**P284 - Readmission after cytoreductive surgery and HIPEC**

G. Peppas, J. Spiliotis, G. Dadoudis, D. Farmakis, D. Vaikos  
Thessaloniki (Greece)

**P287 - Quality of Life after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC): Cancer Survivors' Perspective**

L. F. Falla-Zuniga, M. Caitlin King, K. Pawlikowski, A. Nikiforchin, F. Lopez-Ramirez, P. Barakat, S. Iugai, A. Perinkulam, C. Nieroda, V. Gushchin, A. Sardi  
Baltimore (USA)

**P288 - An international multi-centre prospective study of intraoperative fluid management for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy**

J. Pointon, J. Bell  
Basingstoke (UK)

**P289 - An international multi-centre prospective study of the perioperative anaesthetic management of patients undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC)**

J. Pointon, J. Bell  
Basingstoke (UK)

**P290 - Acutely obstructed patients may be at a higher risk of postoperative infection and morbidity when receiving Cisplatin HIPEC with cytoreductive surgery.**

*P. N. Litkouhi, N. Ahmadi, D. L. Chan, M. Breakeit, S. Barat, P. N. Litkouhi, D. L. Morris Kogarah, Sydney (Australia)*

**P291 - International Variations in Nutritional Support Practice in Patients undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Malignancy: A Global Survey**

*L. Reece, B. Moran, S. Ferrie, N. Ansari, C. Koh, M. Allman-Farinelli, S. Carey Basingstoke (UK) Camperdown, Sydney (Australia)*

**P292 - Combine HIPEC and HITHOC : technique and results.**

*D. Djelil, S. Doat, A. Bardier, O. Lucidarne, M. Pocard Paris (France)*

**P294 - Length of stay correlates with NGT and CT duration: persistently elevated outputs suggest caution in implementing enhanced recovery pathway after CRS and HIPEC**

*S. Ivey, K. Robinson, D. Cox, B. Helmink, C. Scally, P. Mansfield, K. Fournier, A. Uppal, M. G. White Houston (USA)*

**P295 - Morbi-mortality of hyperthermic intraperitoneal surgery performed in intermediate hospital volume: an alternative to centralization?**

*A.C. Ezanno, B. Malgras, M. Pocard Paris, Sain Mande (France)*

**P296 - Enhanced Recovery Protocol Compliance in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Study to assess compliance rates, impact on clinical outcomes and variations in practice**

*S. P. Somashekhar, K.R. Ashwin, A. Fernandes, V. Ahuja, C. Rohit Kumar, Ramachandra Bangalore (India)*

**P297 - The outcome of ERAS Pathways Implementation with Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in patients with Peritoneal Metastasis**

*Wael M.S.A.Gawad, Ahmed Samy, Bahaa Ahmed, Mohga Samy, Abdul Rahman Al Mutawa, Wahid Yousry Gareer Cairo (Egypt)*

**P299 - Continuing Success: Feasibility and Benefits of Enhanced Recovery After Surgery (ERAS) in Multi-Visceral Resections for CRS-HIPEC.**

*J. Wu, C. Jin Seo, N. Brian Shannon, J. Si Min Wong, C.-Ann Johnny, C.Shulyn Chia Singapore (Republic of Singapore)*

**P300 - Is the measurement of sarcopenia associated with the extent of gastrointestinal oncological disease?**

*A. Hang Yue Siu, S. Carey, M. Holyland, D. Steffens, N. Ansari Sydney (Australia)*

**P301 - Surgical Outcomes of Cytoreductive Surgery Performed for Peritoneal Surface Malignancies; An Initial Academic Center Experience.**

*H. Helmi, A.Almajed, R. Alkhawaja, S. Alshammari, T. Bin Traiki Riyadh (Saudi Arabia); Manama (Bahrain)*

**P302 - High dose iron infusion (ferric derisomaltose/isomaltose) in surgical patients: improvement in post-operative clinical condition after CRS-HIPEC procedure**

T. Reis, M. Torres, B. Welcovic, A. Rodas, M. rteiro, M. Arteiro  
Recife (Brazil)

**P303 - Fast-Track Program and ERAS Protocol in CRS-HIPEC: a Better Quality Care and Surgical Results**

T. Reis, L. Taguchi, B. Welcovic, M. Torres, A. Rodas, M. Arteiro, M. Arteiro  
Recife (Brazil)

**P304 - Do patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy benefit from end of procedure abdominal antibiotic lavage?**

R. Wijayawardana, C. Gauci, N. Ahmadi, S. Barat, D. L. Morris  
Kogarah, (Australia)

**P305 - Preoperative intravenous hydration with sodium thiosulfate prevents cisplatin-induced nephrotoxicity in patients undergoing cytoreductive surgery with HIPEC: A retrospective analysis**

E. Vachez, Kefleyesus, Glehen, Ranchoni, Vassali, Al-Hadeedi, Kepenekian, N. Bakrin  
Lausanne (Switzerland); Lyon (France)

**P306 - Outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: 12 years of experience in a national referral centre in Aotearoa New Zealand**

J. Lim, R. Qin, J. Ly, J. Fischer, N. Smith, M. Karalus, L. Wu, R. van Dalen, S. Lolohea  
Hamilton (New Zealand)

**P307 - Retrospective review of vaccination records in patients undergoing splenectomies during peritoneal malignancy surgery**

W. Hossain, M. Carroll, H. Kennedy, R. Wijayawardana, D. L. Morris, S. Adhikari  
Sydney (Australia)

**P308 - Identifying serious illness communications using natural language processing in patients with peritoneal surface malignancies**

L. Choon Kit Wong, N. Brian Shannon, W. Kai Darryl Juan, Y. Liang Khoo, P. Lin Koh, C. Jin Seo, C.-A. Johnny Ong, C. Shulyn Chia, J. Si Min Wong  
Singapore (Republic of Singapore)

**P309 - Fascial dehiscence after CRS-HIPEC for peritoneal metastases. Risk factors analysis.**

E. Pizzolato, C. Cenzi, M. Tonello, F. Lamacchia, C. Riccardo Rossi, P. Pilati, A. Sommariva  
Padova (Italy)

**P310 - Resting Energy Expenditure in patients with Peritoneal Malignancy undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A case series measuring what they need**

Lauren Reece, Morgan Brown, Nabila Ansari, Cherry Koh, Nima Ahmadi, David L. Morris, Margaret Allman-Farinelli, Sharon Carey  
Sydney, Camperdown (Australia)

**P311 - Impact of Anesthesia Handovers on Perioperative and Short-Term Outcomes Following CRS/HIPEC**

S.N. Radomski, T. Kajstura, I. Florissi, N. Winicki, Y. Zeng, J. Jennings, F. M. Johnston, D. J. Berman, J.B. Greer  
Baltimore (USA)

**P312 - Prospective study of factors predicting morbidity in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer – ispsm collaborative study**

S. Sonkusare, S.P. Somashekhar, K.R. Ashwin, R. Yethadka, V. Ahuja, G. Girish, D. Patil, A. Fernandez, K. Aggarwal, U. Baithala, C. Rohit Kumar  
Karnataka (India)

**P313 - Should we consider advanced age or fragility (measured by the mfi index) as exclusion criteria in the selection of patients for CRS-HIPEC?**

C. González de Pedro, D. Aparicio Sánchez, F. Espada Fuentes, F. J. Padillo Ruiz, D. Díaz Gómez Daniel  
Sevilla (Spagna)

**P315 - Enhanced recovery after surgery in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: national survey of peri-operative practice by Indian society of peritoneal surface malignancies- ISPSM COLLABORATIVE STUDY**

B. Udayee Teja, S. P. Somashekhar, S. Deo, S. Rao Thammineedi, H. Chaturvedi, G. Mandakukur Subramanya, R. Joshi, J.Kothari, A. Srinivasan, K.C. Rohit, M. Ray, B. Prajapati, H. Guddahatty Nanjappa, R.Ramalingam, A.Fernandes, K. Rajagopal Ashwin  
Bangalore (India)

**P316 - Implementation of enhanced recovery protocols in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic ovarian cancer following neoadjuvant chemotherapy.**

A. Pandraklakis, C. Liakou, M. LaRussa, A. Stearns, R. Ochoa-Ferraro, T. Duncan, N. Burbos  
Norwich (UK)

**P318 - Navigating the waters between Scylla and Charybdis – Acute Kidney Injury in CRS + HIPEC**

D. Damodaran, S. Vikram, D. Damodaran, Shafeek, Faslu, J. J Alapatt , Gokul, Vishnu Ks, V. Kumar, Chandrashekhar, Althaf  
Kozhikode (India)

**P319 - Compliance and Postoperative outcome following Enhanced Recovery After Surgery (ERAS) guidelines implementation in patients undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS HIPEC)**

D. Damodaran, S. Vikram, D. Damodaran, Shafeek, Faslu, John J Alapatt, Gokul, Vishnu Ks, Vishnu Kumar, Chandrashekhar, Althaf  
Kozhikode (India)

**P322 - Advanced cytoreductive surgery and HIPEC should not be a bloody issue: risk factors for hemotransfusion and strategies for prevention**

A. Petruzzello, L. Baena Carstens, J. Eduardo Leal Nicoluzzi, C.Ontivero, M. Souto Perazzo Valadares, M. Anghinoni  
Curitiba (Brazil)

**P323 - Retrospective cohort: Opioid-free anesthesia with double epidural block better controlling postoperative pain and improving outcome.**

L. Immich, A. E. Serafim, P. Alipo Germano Filho, R. Seitenfus, A. C. Fleig, C. Cereser, E. Dipp, T. Pavao, R. Schrimbeck, F. Ferreira Bueno  
Rio Grande do Sul (Brazil)

**P324 - Case Report: thoracic and lombar peridural and opioid free anesthesia as a safe technique to patient submitted to HIPEC**

L. Immich, A. E. Serafim, V. Lau, R. Seitenfus, A. C. Fleig , C. Cereser, E. Dipp, S. Rosario, W. Pfaffenzeller, S. Santamaria  
Rio Grande do Sul (Brazil)

**P325 - Preoperative nutritional status and length of icu stay of patients submitted to crs and hipec: data from a southern brazilian hospital**

*R. Seitenfus, R. Festugatto Tartari, T. Pavão, L. Freitas, A. Dal Pizzol, C.Cereser, A. C. Fleig, F. Bueno, R. Schrimbeck, D. Scheid  
Rio Grande do Sul (Brazil)*

**P326 - Hyperlactatemia in cytoreductive surgery and HIPEC: don't worry about it (too much)**

*A. Petruzzello, L. Baena Carstens, J. Eduardo Leal Nicoluzzi, C. Ontivero, M. Souto Perazzo Valadares, M. Anghinoni  
Curitiba (Brazil)*

**P327 - Interventional radiology for postoperative haemorrhage following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy**

*S. Okamoto, Y. Gohda, Y. Hayashi, K. Aso, N. Kokudo, H. Yano  
Tokyo (Japan); Southampton (UK)*

**P328 - Assessment of Role of Enhanced Recovery After Surgery (ERAS) Protocols in Patients undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) - A Prospective Feasibility Study**

*P. Das, P. Penumadu, B. Subramanian, P. Subramani  
Pondicherry (India)*

**TREATMENT AND PREVENTION OF PERITONEAL METASTASES FROM GASTRIC CANCER**

**Chairperson:** *Franco De Cian (Genova)*

**P329 - Peritoneal metastases from gastric cancer in a nationwide cohort: incidence, treatment and survival**

*A. Rijken, M.Pape, G. A. Simkens, I.H.J.T. de Hingh, M. D. P. Luyer, J. W. van Sandick, H. W. M. van Laarhoven, R. H. A. Verhoeven, F. N. van Erning  
Utrecht, Amsterdam, Eindhoven (Netherlands)*

**P330 - Prognostic factors for peritoneal metastasis originated from gastric cancer underwent surgery with hyperthermic intraperitoneal chemotherapy following response to induction chemotherapy**

*B. Canbay Torun, E. Sobutay, O. Eren Akbulut, S. Yilmaz, S. Saglam, C. Sezgin, Y. Yonemura, E. Canbay  
Istanbul (Turkey); Kishiwada-Osaka (Japan)*

**P331 - Gastric cancer with peritoneal metastases: a single center outline and comparison of different surgical and intraperitoneal treatments**

*F. Santullo, F. Ferracci, C. Abatini, M. Attalla El Halabieh, C. Lodoli, G. D'Annibale, L. Di Cesare, L. D'Agostino, A. Di Giorgio, A.Strippoli, F.Pacelli  
Roma (Italy)*

**P332 - Retrospective analysis of intraperitoneal paclitaxel (ip PTX) with systematic chemotherapy for gastric cancer with peritoneal metastases**

T. Takayama  
Sapporo (Japan)

**P334 - Pattern of peritoneal dissemination in patients undergoing cytoreductive surgery for gastric peritoneal metastases – a report from phase 1 of the prospective, observational, multi-center PRECINCT study**

A. Bhatt, D. Baratti, D. Biacchi, N. Benzerdjeb, A. Buseck, I. Bonnefoy, S. Barat, M. Deraco, D. Morris, A. Soudka, M. Alyami, V. Gushchin, N. Shah, G. Adeleke, S. Stanford, V. Mark Samuel, K. Cummins Perry, B. El Khannousi, S. Khouchoua, N. El Bahaoui, U. Sarpel, D. Labow, N. Khajouejinejad, S. Troob, F. Mohammad, B. Moran, E. Levine, V. Kepenekian, P. Rousset, P. Sammartino, L. Villeneuve, A. Sardi, O. Glehen  
Ahmedabad (India); Milano, Roma (Italy); New York, Baltimore, Winston-Salem (USA); Sydney (Australia); Najran (Saudi Arabia); Basingstoke (UK); Rabat (Morocco); Lyon (France)

**P335 - Combined intraperitoneal and systemic chemotherapy as adjuvant or perioperative chemotherapy for patients with type 4 scirrhous gastric cancer without peritoneal metastasis: PHOENIX-GC2 trial**

H. Ishigami, T. Omori, Y. Tsuji, H. Shinohara, H. Yabusaki, D. Kobayashi, S. Ito, D. Takahari, H. Hata, H. Yamashita, T. Kusumoto, M. Kanda, H. Yamaguchi, K. Kobayashi, M. Morita, J. Kinoshita, K. Oba, J. Kitayama, Y. Seto  
Tokyo, Osaka, Sapporo, Nishinomiya, Niigata, Komaki, Nagoya, Fukuoka, Shimotsuke, Nagasaki, Kanazawa (Japan)

**P336 - Emerging treatment modalities for gastric cancer with peritoneal metastases: a systematic review**

M. W. Welten, L. Galanos, I. E. G. van Hellemond, G. J. Creemers, M. D. P. Luyer, I. H. J. T. de Hingh  
Eindhoven (Netherlands)

**P337 - Docetaxel versus paclitaxel for peritoneal metastasis originated from gastric cancer underwent surgery with hyperthermic intraperitoneal chemotherapy following response to induction chemotherapy**

B. Canbay Torun, Y. Yonemura, E. Canbay  
Istanbul (Turkey); Kishiwada-Osaka (Japan)

**P338 - CD44-positive peritoneal cancer cells as a source of postoperative peritoneal recurrence**

S. Murata, K. Takebayashi, S. Kaida, A. M. Sihombing, M. Shimoji, H. Kodama, A. Tokuda, M. Kojima, R. Ohtake, H. Maehira, H. Mori, T. Miyake, E. Mekata, M. Tani  
Shiga (Japan)

**P339 - Phonozen-mediated photodynamic therapy in a mouse model of peritoneal carcinomatosis**

Hyoung-Il Kim, Sung-Ho Lee, Su-Jin Shin, Jong-Hyun Park, Jae Eun Yu, Sang Won Lee, Seung Hee Yang, Layla Pires, B. C. Wilson  
Seoul (South Korea)

**P340 - Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer with limited peritoneal carcinomatosis: a single center experience**

F. Casella, F. Meloni, R. Rigoli, C. Puccio, M. Bencivenga, G. de Manzoni  
Verona (Italy)



**P341 - Cytoreductive surgery and HIPEC for gastric carcinomatosis: where do we have to push the limit? A single-team experience**

*P. Fugazzola, J. Viganò, N. Allievi, L. Cobiانchi, T. Dominioni, S. Magnone, M. Tomasoni, L. Ansaloni.  
Pavia, Bergamo,*

**P342 - Conversion surgery for gastric cancer with peritoneal metastasis during IP-PTX combined with SOX.**

*S. Saito, H. Yamaguchi, R. Kanamaru, H. Ohzawa, K. Kurashina, K. Takahashi, Y. Kaneko, Y. Hosoya, A.K. Lefor, N. Sata, J. Kitayama  
Tochigi (Japan)*

**P344 - CRS/HIPEC for Peritoneal Metastases from Gastric Cancer: Early Experience in Bogotá, Colombia**

*A. A. Nieves Rico, J. L. Gomez-Mayorga, J. M. Otero Bernal, E. E. Londoño-Schimmer, C. E. Cetares-Salas, M. C. Mora-Lozano, N. Cortes-Murgueitio, A. Bastidas-Santacruz, F. Arias-Amezquita  
Bogotá (Colombia); Massachusetts (USA)*

**P346 - PIPAC EstoK01: randomized phase II study on Doxorubicin/Cisplatin Pressurized Intra Peritoneal Aerosol Chemotherapy in gastric peritoneal metastasis: postoperative and oncological outcomes**

*C. Eveno, V. Kepenekian, C. Brigand, V. De Franco, O. Sgarbura, S. Fontanier, I. Sourrouille, J. J. Tuech, D. Goéré, A. Mariani, M. Resche-Rigon, M. Pocard  
Lille, Lyon, Strasbourg, Angers, Montpellier, Limoges, Villejuif, Rouen, Paris (France)*

**P347 - Multimodal Approach for Treatment of Gastric Cancer with Peritoneal Metastasis in a low-income Population; Integrating Staging Laparoscopy, Perioperative Intraperitoneal Chemotherapy, and HIPEC. Our Initial Experience.**

*G. Flores Ayala, L. Romero Esaul, C. Vazquez Limon Juan  
Guadalajara (Mexico)*

## LAPAROSCOPIC CRS HIPEC

**Chairpersons:** *Rea Lo Dico (Rome) - Alvaro Arjona Sanchez (Cordoba)*

---

**P348 - Peritoneal Surface malignancies in low income countries – ‘Paucity of Funds is NOT a Surgical Barrier’; A retrospective analysis of the outcomes of treatment with Government aided funding schemes**

*J. Kumar Pandey, S. Basu  
Patna (India)*

**P349 - Cytoreduction and hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei syndrome and peritoneal metastases from colorectal cancer: an assessment of management in Latvian Oncology center**

*A. Pcolkins, Antons Rudzats, I. Jelovskis, A. Sivins, M. Melnalksne, A. Marija Lescinska  
Riga (Latvia)*

**P350 - Simultaneous umbilical reconstruction during cytoreductive surgery; feasibility, technical approach, and outcomes**

*E. Cheng, P. Yang, S. Khor, J. Mui, R. Wijayawardana, N. Ansari, D. L. Morris, N. Ahmadi  
Sydney (Australia)*

**P351 - Overall survival and morbidity are not associated with advanced age for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a single center experience**

*E. Cheng, Raphael Shamavonian, J. Mui, R. Hayler, J. Karpes, R. Wijayawardana, S. Barat, N. Ahmadi, D. L. Morris  
Sydney (Australia)*

**P352 - Robotic Assisted CRS-HIPEC**

*H. Alhabes, M. Alzamanan, S. Almowallad, M. Alyami  
Najran (Saudi Arabia)*

**P353 - Barriers to the Integration of Palliative Care in a Peritoneal Surface-based Malignancy Unit**

*S. Hui Xian Cheok, D. Juan Wen Kai, B. Paik, Koh Poh Lin, O. Chin-Ann Johnny, J. Seo Chin Jin, C. Chia Shulyin, J. Wong Si Min  
Singapore (Republic of Singapore)*

**P357 - Outcomes of Minimal access cytoreductive surgery (M-CRS) and HIPEC/EPIC vs Open cytoreductive surgery (O-CRS) and HIPEC/EPIC in Patients with Peritoneal Surface Malignancies: A Meta-analysis.**

*A. Pawar, V. Warikoo, A. Salunke, M. Sharma, S. Pandya  
Ahmedabad (India)*

**P358 - Short term complications and overall survival outcomes in diaphragmatic interventions in cytoreductive surgery and intraperitoneal chemotherapy**

*T. Williams, S. Barat, D. Morris  
Sydney (Australia)*

**P360 - Open versus closed technique for administration of heated intraperitoneal chemotherapy (HIPEC): morbidity and mortality outcomes from a high-volume centre**

*Dritsas S., Hassan S., O'Dwyer S., Aziz O., Sutton P., Wang X., Renehan A., Wilson M., Selvasekar C., Clouston H., Wild J., Mathur M., Fish R.  
Manchester (UK)*

**P361 - Overwhelming Post-splenectomy Infections (OPSI) after complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a prospective observational study**

*S. Stanford, P. Porter, N. Ahmadi, N. Preston, J. Brady, H. Whitebread, C. Nesari, T. Cecil, S. Dayal, A. Tzivanakis, F. Mohamed, V. Mark Samuel, B. Moran  
Basingstoke (UK); Sydney (Australia)*

**P362 - A multicenter analysis of CRS±HIPEC for peritoneal metastasis of hepatocellular carcinoma in Japan**

*K. Yamanaka, M. Umeda, R. Nishitai, T. Kitai, Y. Yonemura  
Hyogo, Osaka (Japan)*

**P363 - Effects of Hyperthermic Intraperitoneal Intraoperative Chemotherapy (HIPEC) to Pancreatic Carcinoma with Peritoneal Metastasis**

*Y. Yonemura, S. Sako, H. Ishibashi, A. Mizumoto, M. Ichinose, N. Takao, B. Canbay Torun, E. Canbay  
Kishiwada Osaka, Shiga (Japan); Istanbul (Turkey)*

**P364 - Outcomes and Quality of Life after Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC): A Single Asian Tertiary Centre Experience**

*J. Hendrikson, C. Jin Seo, J. Si Min Wong, C.-A. Johnny Ong, C. Shulyin Chia  
Singapore (Republic of Singapore)*

**P365 - BromAc® does not interfere with the healing of colon anastomosis in HIPEC in vivo model.**

A. H. Mekkawy, M. Breakeit, K. Rahman, Krishna Pillai, S. Badar, J. Akhter, S. J. Valle, D. L. Morris  
Sydney (Australia)

**P366 - Oncological Outcomes and Hospitalization Cost of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) closed and open abdomen techniques: Results from two French expert centers**

A. C. Ezanno, S. Chkair, J. Quesada, J. Abba, B. Malgras, B. Trilling, P. Sage, S. Bouvet, A. Foote, A. Aime, O. Glehen, M. Pocard, C. Arvieux, F. Tidadini  
Lyon, Paris, Saint Mandé, Grenoble, Nîmes, Montpllier, Saint Mandé (France)

**P367 - Use of natural language processing for registry development in peritoneal surface malignancies**

N. Brian Shannon, L. Choon Kit Wong, M. Nakayama, N. Tuan Anh Tran, L. Tim-Ee Cheng, C. Hua Thng, H. Rizal Bin Abdullah, J. Wen Kai Darryl, L. Ming Jie Demi, C.-A. Johnny, C. Jin Seo, C. Shulyng Chia, J. Si Min Wong  
Singapore (Republic of Singapore); Los Angeles (USA)

**P368 - Long term Survival in patients treated with Cytoreductive surgery with or without HIPEC for Peritoneal surface malignancies - A report from the Indian HIPEC Registry.**

S. Sinukumar, P. Kammar, M. Ray, D. Damodaran, F. Rajan, A. Srinivasan, S. Mehta, V. Mahajan, A. Bhatt  
Maharashtra (India)

**P369 - In-hospital costs are associated with the severity of post-operative complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy**

S. Jarrar, C. E. Koh, P. Makker, N. Ansari, Y. Huang, B. Moran, D. Steffens  
Sydney (Australia)

**P372 - The influence of postoperative morbidity on long-term quality of life trajectories following cytoreductive surgery – A prospective cohort study**

D. Steffens, P. Makker, M. Solomon, S. Karunaratne, H. Solanki, B. Moran, C. Koh  
Sydney (Australia); Hampshire (UK)

**P373 - Evaluating variation in healthcare equity amongst metropolitan versus regional patients undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy**

A. Hang Yue Siu, D. Steffens, S. Karunaratne, H. Solanki, N. Ahmadi, C. Koh  
Sydney (Australia)

**P374 - The Perspectives of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy In the Management of Rare -Unclassified tumours with Peritoneal Metastasis: A-Single Centre Experience.**

W. Yousry Gareer, W. M. S. A. Gawad, H. Abdel Mageed, W. Akmal  
Cairo (Egypt)

**P375 - Psychological and biobehavioral late effects after surgery for peritoneal metastases from colorectal cancer.**

Ro. Balachandran, H. Vind Thaysen, P. Christensen, B. Zachariae, L. Hjerrild Iversen  
Aarhus (Denmark)

**P376 - Bidirectional chemotherapy for extended peritoneal disease: monocentric experience after the implantation of more than 100 INTRAPERITONEAL CATHETERS**

Marie-Julie Lardinois, Surgical Oncology, Gustave Roussy, M. Gelli, C. Smolenschi, E. Fernandez De Sevilla, L. Benhaim, V. Boige, M. Ducreux, I. Sourrouille Villejuif (France)

**P377 - Pattern of regional lymph node involvement secondary to peritoneal metastases in patients undergoing cytoreductive surgery- results from phase 1 of the PRECINCT study**

A. Bhatt, D. Baratti, D. Biacchi, N. Benzerdjeb, A. Buseck, I. Bonnefoy, S. Barat, M. Deraco, D. Morris, A. Soudka, M. Alyami, V. Gushchin, N. Shah, G. Adeleke, S. Stanford, V. Mark Samuel, K. Cummins Perry, B. El Khannousi, S. Khouchoua, N. El Bahaoui, U. Sarpel, D. Labow, N. Khajouinejad, S. Troob, F. Mohammad, B. Moran, E. Levine, V. Kepenekian, P. Rousset, P. Sammartino, L. Villeneuve, A. Sardi, O. Glehen Ahmedabad (India); Milano, Roma (Italy); New York, Baltimore, Winston-Salem (USA); Sydney (Australia); Najran (Saudi Arabia); Basingstoke (UK); Rabat (Morocco); Lyon (France)

**P378 - Does Peritoneal Sarcomatosis of Uterine origin treatable with CRS and HIPEC? Experience from Tertiary Referral Oncology Centre, India**

M.D. Ray, N. Premanand, D. Goel, S.V.S. Deo New Delhi (India)

**P379 - Economic Viability of Cytoreductive Surgery and HIPEC in Brazilian health system (SUS)**

T. Reis, B. Welcovic, M. Torres, L. Taguchi, A. Rodas, M. Arteiro, M. Arteiro Recife (Brazil)

**P380 - Growing teratoma syndrome: Case report of complete cytoreduction.**

A. Urbano Ruiz, B. Escorel Costa Fava, R. Elias Rego, M. Antonio Guaraldo da Silva, B. Latrônico Palma, E. Araujo Falcao, M. Cristina Rodrigues da Silveira, M. Louise Rodrigues Barbosa da Silva São Paulo (Brazil)

**P381 - "Barrios' Technique implementation to colorectal anastomosis avoiding ostomies in Cytoreductive Surgeries and HIPEC in a single center of Peritoneal Malignancies**

A. Urbano Ruiz, B. Latrônico Palma, R. Elias Rego, M. Antonio Guaraldo da Silva, B. Escorel Costa Fava, E. Araujo Falcao, M. Cristina Rodrigues da Silveira, M. Louise Rodrigues Barbosa da Silva São Paulo (Brazil)

**P382 - Impact of Diverting Ostomy on Cytoreductive Surgery with Multiple Large Intestinal Anastomoses and HIPEC: A Propensity Score Matched Study**

A. Kefleyesus, V. Kepenekian, I. Bonnefoy, G. Guinez, O. Sgarbura, N. Elbahaoui, C. Eveno, A. Fernandes, S.P. Somashekhar, D. Clerc, H. Teixeira-Farinha, M. Hübner, O. Glehen Lyon, Montpellier, Lille (France) Bengaluru (India), Lausanne (Switzerland)

**P383 - BromAc® (Bromelain plus N-acetylcysteine) enhances the sensitivity of tumour cells to chemotherapeutic agents (Mitomycin, Gemcitabine, 5-FU and Oxaliplatin) in HIPEC in vitro model.**

K. Rahman, S. Badar, A.H. Mekki, M. Breakeit, K. Pillai, J. Akhter, S. J. Valle, D.L. Morris Sydney, Mucpharm (Australia)

**P384 - Long-term survival in patients with peritoneal sarcomatosis undergoing cytoreductive surgery plus HIPEC**

G. Salti, I. Salti, S. Logarajah Chicago (USA)

**P385 - Mitomycin C in HIPEC: a proposal to use abdominal cavity volume for drug dosage**

G. Salti, S. Logarajah  
Chicago (USA)

**P386 - Early Referral is Critical to Long-Term Outcome for Peritoneal Metastasis Treated with Cytoreductive Surgery/ Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)**

C. Zhang, D. D. Hegeholtz, P. Sharma, M. Gutierrez, J. Schneider, V. Shostrom, J. M. Foster  
Omaha (USA)

**P387 - Grading of surgical complications following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). A comparison of current classification systems**

C. Koh, Y. Lim, D. Steffens, Y. Hunag, B. Moran  
Sydney, Basingstoke (Australia)

**P388 - Experience, outcomes and lessons learnt from the first 6 years at a peritoneal malignancy centre.**

N. Ansari, D. Steffens, N. Ahamdi, B. Moran, K. McBride, H. Solanki, M. Solomon  
Sydney, Basingstoke (Australia)

**P390 - First Indian study reporting adoption of ERAS in CRS HIPEC:**

**Time to Adopt, Evolve & Improve - ISPSM Collaborative study**

S.P. Somashekhar, Y. Ramya, K.R. Ashwin, V. Ahuja, G. Girish, M. Darshan Patil, A. Kumar  
Namachivayam, K. Agarwal, B. Teja Udayee, S. Sonkusare, C. Rohit Kumar  
Bangalore (India)

**P392 - Cytoreductive surgery and HIPEC for peritoneal sarcomatosis in pediatrics and young adults. A single-center experience**

A. Sommariva, F. De Corti, E. Pizzolato, M. Gortan, M. Tonello, C. Cenzi, An. Brunello,  
Gi. Bisogno, P. Pilati, P. Gamba  
Padova (Italy)

**P393 - Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Peritoneal Carcinomatosis: Analysis of 1759 Consecutive Cases**

Ru Ma, Yan-Dong Su, Xin Zhao, Rui Yang, Yan Li  
Beijing (China)

**P394 - Correlation of Peritoneal Regression Grading Score (PRGS) with survival outcomes in advanced ovarian cancer undergoing cytoreductive surgery and HIPEC – ISPSM Collaborative Study**

S. Sonkusare, S.P. Somashekhar SP, K.R. Ashwin, S. Rakshit, V. Ahuja, G. Girish, D. Patil,  
A.Fernandez, Ku. Aggarwal, U. Baithala, C. Rohit Kumar  
Bengaluru (India)

**P395 - Peritoneal malignancy CT surveillance: Frequency and typical locations of missed disease.**

J. El-Sheikha, O. Duxbury, D.Patel, N.Shah, A. Thrower  
Hampshire (UK)

**P396 - Analysis of the direct healthcare costs of cytoreductive surgery and hipec program for the treatment of peritoneal carcinomatosis in the national health system.**

**The funder's perspective**

C. González de Pedro, D. Aparicio Sánchez, F. Espada Fuentes, F. J. Padillo Ruiz, D. Díaz Gómez,  
Sevilla (Spain)

**P397 - The impact of complications on one-year treatment-related healthcare costs in patients who undergo cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of colorectal peritoneal metastases.**

*B. J.L. Kooijman, J. E.K.R. Hentzen, W. Helfrich, E. M. Ploeg, R. J. van Ginkel, B. L. van Leeuwen, L. B. Been, J. M. Klaase, P.H.J. Hemmer, C.S. van Hilst, S. Kruijff Groningen, Zwolle (Netherlands)*

**P399 - Peritoneal metastases of gallbladder cancer successfully treated by three CRS with HIPEC**

*F.M. Regueira, P. Marti- Cruchaga, G. Zozaya, A. Chopitea, R. Calderón, C. Sánchez-Justicia, A. Almeida, F. Rotellar Pamplona (Spain)*

**P401 - Evaluation of complications in patients underwent hipec and crs: analysis of a single western center**

*F. Di Schiena, G. Di Lieto, N. Natalizi, E. Marino, L. Graziosi, A. Donini Perugia (Italy)*

**P403 - Role of Cytoreductive Surgery and Hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis in Indian settings – A tertiary Cancer Care Centre experience.**

*A. S. Ramakrishnan, P. Vivek, N. Madhuri, R. G. S. Madhupriya, E. Hemant Raj Chennai (India)*

**P404 - Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Desmoplastic Small Round Cell Tumor in young patient: Case Report**

*L. Hudon, M.Soucisse, J. Noujaim, P.Dubé, L.Sideris Montreal (Canada)*

**P405 - Fertility and Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy**

*H. Benvenisti, D. Assaf, E. Mor, D. Hadar, E. Aviran, A. Ben-Yaacov, M. Adileh, D. Zippel, Sh. Laks, A. Nissan Ramat Gan (Israel)*

**P406 - An Epic Success: Developing a Reportable CRS/HIPEC Operative Note in an Electronic Health Record System**

*M. Caitlin King, F. Lopez-Ramirez, K. Campbell, A.Sardi, V. Gushchin Baltimore (USA)*

**P407 - Assessment of health related quality of life(HRQOL) and distress in patients suffering from peritoneal cancers treated at Tertiary Cancer Hospital in India.**

*N. Katdare, R. Williams Maharashtra (India)*

**P408 - Management of Peritoneal Carcinomatosis in Gastrointestinal Stromal Tumors: A Case Report and Surgical Approach**

*M. Rojas Estevez, C. Díaz López, V. Concepción Martín, J. Abellán Fernández, R. Haresh Gianchandani Moorjani, R. Orti Rodríguez, J. Manuel Sánchez González, E. Moneva Arce, M.Ángel Barrera Gómez Santa Cruz de Tenerife (Spain)*

**P409 - Prognostic Factors for Overall Survival in Cytoreductive Surgery and HIPEC: A single-center analysis**

*M. F. Pascoal, F. Brito Silva, S. Carvalhal, M. Limbert, N.Abecasis Lisboa (Portugal)*

**P410 - COVID 19 pandemic impact on the availability and implementation of CRS + HIPEC procedures in patients with peritoneal carcinomatosis in Wrocław Comprehensive Cancer Center**

*K. Szewczyk, M. Bebenek  
Wrocław (Poland)*

**P411 - Robotic approach Improves Perioperative Outcomes for Cytoreduction and HIPEC in Gastric Cancer**

*T. E. Grotz, E. Buckarma  
Rochester (USA)*

**TRAINING & TACHING ON PSM**

**Chairperson:** *Andreas Brandl (Heidelberg)*

---

**P413 - Overcoming of Learning Curve in CRS-HIPEC: a program implementation into public and private field**

*T. Reis, L. Taguchi, A. Rodas, M. Arteiro, M. Reis  
Recife (Brazil)*

**P414 - Practice patterns, attitudes, and knowledge among clinicians regarding HIPEC and PIPAC: ISPSM Collaboration Study.**

*A. Kushal, S.P.Somashekhar, Ashwin, C. Rohit Kumar, A. Vijay, G. Girish, A. Marion Fernandes, D. Patil, U. Teja Bathala, Shipra  
Bangalore (India)*

**P415 - Implementation and results of a peritoneal surface malignancy program in a developing country**

*S. Diaz, F. Alberto Quintero, V. Ramos, M. Clara Arroyave  
Rionegro (Colombia)*

**P416 - Development of an assessment tool for training in cytoreductive surgery and HIPEC for peritoneal malignancy**

*N. Allievi, V. Mark Samuel, A. Tzivanakis, S. Dayal, T. Cecil, F.Mohamed, B. Moran  
Basingstoke (UK)*

# General Information

**CONGRESS VENUE**  
PALAZZO DEL CINEMA  
Lungomare Marconi, 30  
30126 Lido di Venezia

## ORGANIZING SECRETARIAT



First Class - Meetings and Conferences  
*Sede Milano*  
Via Vittoria Colonna 40 – 20149 Milano  
psogi2023@fclassevents.com  
www.fclassevents.com

The Organizing Secretariat will be available to the participants at the congress venue during the following times:

- Wednesday, October 4<sup>th</sup> from 07:30 to the end of the works
- Thursday, October 5<sup>th</sup> from 07:00 to the end of the works
- Friday, October 6<sup>th</sup> from 07:00 to the end of the works

## REGISTRATION

Congress attendance is subject to online registration by Tuesday, September 19th, 2023. After the deadline, it will be possible to register directly at the congress venue.

	Early rate (3 days) until 30 June	Late rate (3 days) until 19 September	Onsite rate (3 days)
REGISTRATION PHYSICIAN	650.00 €	800.00 €	900.00 €
REGISTRATION RESIDENTS/FELLOWS AND STUDENT/ADVANCED PRACTICE CLINICIANS	250.00 €	350.00 €	450.00 €
REGISTRATION NURSES ALLIED HEALTH PROFESSIONAL	150.00 €	250.00 €	350.00 €

All prices mentioned are in Euro, VAT 22% is not included

### The registration fee includes:

- Participation in all scientific sessions
- Congress materials and a name badge
- Access to the exhibition area and poster area
- Coffee breaks and lunches, according to the programme
- Certificate of Attendance



## **PAYMENT METHOD**

- Online - Bank transfer and credit card
- Onsite - ATM and credit card

## **CANCELLATIONS AND REFUNDS**

Cancellations received by 31 July 2023, will entitle to a refund of the amount paid minus 30% for administrative costs. Cancellations received after this date will not entitle to a refund. However, all refunds will be made after the Congress is held.

All refund/cancellation requests must be provided in writing and emailed to [psogi2023@fclassevents.com](mailto:psogi2023@fclassevents.com) by 31 July 2023

## **BADGE**

At the time of registration, each registered participant will be given a name badge which must always be shown in order to access the classrooms where the scientific sessions are held, the exhibition area and the catering services.

## **CERTIFICATE OF ATTENDANCE**

The certificate of participation can be downloaded online after completing the evaluation questionnaire. The Organizing Secretariat will send an e-mail to all participants on October 9th containing useful information to download it.

## **CLOAKROOM AND LUGGAGE STORAGE**

A cloakroom and left-luggage office will be available on the ground floor.

## **SOCIAL DINNER**

The social dinner will be held on October 5<sup>th</sup> at:

## **PALAZZO DEL CASINÒ**

Lungomare Guglielmo Marconi, 1861, 30126 Lido di Venezia

Entry will be permitted only upon presentation of the relative invitation received at the time of registration for the Congress.

## **WI-FI**

Network:PSOGICONGRESS

Password: Psogi2023!

# CME Accreditation

Il 13<sup>th</sup> International Congress on Peritoneal Surface Malignancies, Venezia 4-6 ottobre 2023 è inserito nel Piano Formativo anno 2023 First Class - Provider nr. 362 ed è stato accreditato presso la Commissione Nazionale per la Formazione Continua con **Obiettivo Formativo**:

18 - Contenuti tecnico-professionali (conoscenze e competenze) specifici di ciascuna professione, di ciascuna specializzazione e di ciascuna attività ultra-specialistica, ivi incluse le malattie rare e la medicina di genere per le seguenti figure professionali:

PROFESSIONE	DISCIPLINE
Biologo	<i>Biologo</i>
Medico Chirurgo	<i>Genetica Medica, Oncologia, Chirurgia Generale, Ginecologia e Ostetricia, Anestesia e Rianimazione, Patologia Clinica (Laboratorio di Analisi Chimico-Cliniche e Microbiologia), Radiodiagnostica, Medicina Generale (Medici di Famiglia), Cure Palliative</i>
Infermiere	<i>Infermiere</i>

Il congresso è stato accreditato per un numero massimo di n. 600 partecipanti.

Oltre tale numero e per professioni/ discipline differenti da quelle accreditate non sarà possibile rilasciare i crediti formativi.

Si precisa che i crediti verranno erogati a fronte di una partecipazione del 90% ai lavori scientifici (farà fede esclusivamente l'orario di ingresso e uscita riportato nel foglio firme) e del superamento della prova di apprendimento con almeno il 75% delle risposte corrette.

L'evento, ID ECM 362-391543, ha ottenuto 5,7 crediti formativi

# UEMS/EACCME Accreditation



The 13th PSOGI International Congress on Peritoneal Surface Malignancies, 04/10 – 06/10, 2023, Venice has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 18,5 European CME credits (ECMEC®s).

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.


Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™.

**Information on the process to convert EACCME® credit to AMA credit can be found at [www.ama-assn.org/education/earn-credit-participation-international-activities](http://www.ama-assn.org/education/earn-credit-participation-international-activities).**

The attendance of delegates will be tracked each day during the Congress. Each participant could only receive the number of credits he/she is entitled to, according to his/her actual participation at the event, and only once he/she has completed the evaluation form. The process and detailed information will be sent by the Organizing Secretariat after the Course.


# Exhibition area

The 13<sup>th</sup> PSOGI International Congress  
on Peritoneal Surface Malignancies




# GROUND FLOOR

## PALAZZO DEL CINEMA (MOVIE PALACE)



# FIRST FLOOR



# The PSOGI Congress

has been realized thanks to the

## Platinum Sponsor



## Gold Sponsor



solution...future ready




## Supporters





The 13<sup>th</sup> PSOGI International Congress  
on Peritoneal Surface Malignancies





[www.psogicongress2023.com](http://www.psogicongress2023.com)

Provider ECM 362 - Segreteria Organizzativa



First Class - Meetings and Conferences  
Via Vittoria Colonna, 40 - 20149 Milano